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ABSTRACT
Survival rates of intensive care unit (ICU) patients are consistently increasing. This 
new patient population has recently gained increased recognition as they suffer 
from psychological, physical, and cognitive impairments in the years to come after 
ICU discharge. These symptoms are collectively referred to as the post-intensive 
care syndrome (PICS). Importantly, the underlying pathophysiology of PICS is 
unclear, but in many ways consistent with a persistent, non-resolving inflamma-
tion. In this context, high mobility group box 1 (HMGB1), a prototypical alarmin 
involved in both sterile and infectious inflammation, has gained interest, particu-
larly since animal studies indicate that HMGB1 promotes neuroinflammation and 
cognitive impairment.
This thesis investigates aspects of PICS in ICU survivors, including subjective 
and objective cognitive function, physical performance, and markers of inflam-
mation. Patients were included in two cohorts designed for ICU follow-up studies. 
In study I, the association between sepsis and delirium during ICU stay and symp-
toms of psychological distress (Hospital Anxiety and Depression Scale (HADS) 
and Post-traumatic Stress Symptoms Scale-10 (PTSS-10)) and self-rated cognitive 
function (Cognitive Failures Questionnaire (CFQ)) after three months were inves-
tigated. There was no significant association between sepsis or delirium at ICU 
stay and self-rated cognitive function at the three months follow-up. In contrast, 
there was a strong significant correlation between patients’ self-rated cognitive 
function and symptoms of depression, anxiety, and PTSD. 
Studies II-IV investigate a 12 months follow-up cohort of ICU survivors. Patients 
were examined at the ICU follow-up clinic at three, six, and twelve months after 
ICU discharge. They underwent formal neuropsychological testing, performed 
physical tests, and responded to three questionnaires on psychological distress 
and subjective cognitive function (HADS, PTSS-10, CFQ). Blood samples were 
collected at the three and six-month follow-up visits.
Study II investigates whether patients´ subjective cognitive function correlates 
to objectively measured cognitive function. Answers on the CFQ were analyzed 
together with outcomes on the Cambridge Neuropsychological Test Automated 
Battery (CANTAB). There was no clinically relevant correlation between subjective 
and objective cognitive function as measured here. We conclude that subjective 
cognitive function tests in ICU survivors must be interpreted with caution and that 
both subjective and objective testing may be necessary to adequately ascertain 
cognitive function in ICU survivors.
In study III, the association between plasma HMGB1 and objective cognitive 
function measured in four different cognitive domains (executive function, visual 
memory, sustained attention, working memory) was investigated. Interestingly, 
plasma levels of HMGB1 were significantly elevated in the ICU, at discharge, and 
at the three- and six-months follow-up visits as compared with reference popula-
tions. Elevated plasma levels of HMGB1 were associated with reduced sustained 
attention at the three- and six-month follow-up visits. Based on these findings, 
further follow-up studies on HMGB1 biology in ICU survivors are warranted to 
investigate the potential for therapeutic targeting of HMGB1 function in preven-
tion of cognitive impairment in ICU survivors. 
In study IV we explore the association between plasma HMGB1 and physical 
performance at ICU follow-up. We observed no significant association between 
levels of plasma HMGB1 and the three physical tests performed (i.e., 6-min walk 
test, timed stands test, handgrip strength test). 
In conclusion, this thesis provides new insights on objective and subjective cogni-
tive function, psychological distress, and markers of inflammation in ICU survi-
vors. Future work may build on this knowledge to improve the identification and 
treatment of at-risk subjects in this vast and growing patient population.
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11 INTRODUCTION
1.1 The history of intensive care
In 1952, the polio epidemic ravaged Denmark. Professor Lassen, chief physician 
of the Blegdam Hospital, watched his patients die from respiratory failure due to 
paralysis from poliomyelitis. At that time, the hospital had very limited resources 
in terms or respirators, and Professor Lassen stood powerless in his urge to provide 
treatment for patients that succumbed to polio. He then contacted Bjørn Ibsen, an 
anesthetist trained in the U.S, with the hope that his newly gained knowledge in 
modern anesthesia would come to help (1). Ibsen came to Blegdam Hospital in late 
August 1952, where, at that time, a 12-year-old girl with severe polio was admitted. 
In a theater full of colleagues, the young patient was tracheotomized under local 
anesthesia, and Ibsen could, after general sedation, successfully deliver positive 
pressure ventilation manually (2). Positive pressure ventilation was new in the field 
of anesthesia, and when Ibsen’s method was applied to all polio patients, mortality 
rates quickly dropped from approximately 85 % to 30 %. Medical students were 
recruited for the management of hand ventilation, and designated wards were built 
to provide around-the-clock medical care (Figure 1). This was the beginning of a 
new era; the first intensive care unit (ICU) was established.  
Figure 1: An 8-year-old girl being manually ventilated through tracheostomy in 1952. (3)
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2.1 Post-intensive care syndrome
Several million patients are cared for in ICUs in Europe every year, due to life-
threatening illness or injury (4). As the survival rates after intensive care are 
consistently increasing (5) it has become more recognized that ICU patients suf-
fer from debilitating sequels in the years to come after primary survival. These 
problems include cognitive impairment, post-traumatic stress disorder (PTSD), 
depression, functional disabilities, and reduced quality of life in the months to 
years after ICU discharge (6-11). At a stakeholder conference in North America 
in 2010, the ICU community came to consensus on these emerging symptoms to 
improve long-term outcomes in ICU survivors, and the term post-intensive care 
syndrome (PICS) was introduced (12). PICS is defined as new onset or worsening 
of psychological, physical, or cognitive impairments that persist past the acute care 
and hospitalization. The prevalence of PICS varies, but 25-50 % of patients suffer 
from symptoms from some component of PICS after ICU discharge (8, 13-16). In 
the last decade, PICS has become recognized as a major socio-economic burden, 
as the consequences that PICS comprises impede patients’ return to the level of 
function and employment they had before onset of illness (17, 18).
2.1.1 Mental impairment in PICS
Facing death or being severely ill greatly impacts the psychological well-being of 
ICU survivors, as adverse experiences from the ICU require coping with the new 
perspectives and life-conditions that most likely will occur. The stress and physi-
ological changes that take place during ICU stay will affect the recovery even of 
patients with good family networks and high coping ability. Up to 20 % of ICU 
survivors suffer from depression, anxiety, and PTSD, and risk factors include his-
tory of psychological problems, female gender, and education level (9, 10, 19). The 
prevalence of depression is also significantly higher in ICU survivors than in the 
general population (8 %) (20). Both intervention and rehabilitation have proven 
challenging in this patient group (16, 21, 22). Nevertheless, early screening to 
identify patients at risk and the use of ICU diaries to help with coping has emerged 
as possible helpful interventions (23, 24). PICS symptoms do, however, often co-
occur, and understanding the relationship between the different domains of PICS 
is one of many challenges the scientific and clinical ICU community faces (16).
32.1.2 Physical impairment in PICS
Physical disabilities after critical illness include loss of muscle mass, muscular 
weakness, reduced lung capacity, nerve dysfunction, and fatigue. The co-occurrence 
of these symptoms is called “ICU-acquired weakness”, and is present in almost 
half of patients with sepsis or multi-organ failure (25). A diagnose of ICU-acquired 
weakness includes critical illness myopathy, polyneuropathy, and neuromyopathy 
assessed through electrophysiological tests, and the neuropathy is characterized by 
axonal degeneration without demyelination (26). ICU-acquired weakness is associ-
ated with prolonged ICU and hospital stay due to reduced functional capacity, and 
therefore difficulties in weaning patients from mechanical ventilation (27). Apart 
from functional disabilities, ICU-acquired weakness has also been found to be an 
independent predictor of hospital mortality (28). The physical disability in ICU-
acquired weakness may persist for years after ICU discharge, and a prospective 
follow-up study of ARDS patients showed reduced physical capacity for up to five 
years (14, 29). These impairments, together with the other PICS symptoms, affect 
the trajectory of recovery and have an impact on both patients’ daily function as 
well as their ability to return to their previous employment (18, 30).
The pathophysiology behind ICU-acquired weakness is still unclear, but multiple 
factors have been suggested (31). These include microvascular ischemia due to 
disturbed microcirculation, which results in neuronal and mitochondrial injury 
and axonal degeneration. Additionally, the catabolic state and immobility, which 
occur early in ICU patients, can lead to skeletal muscle wasting and loss of muscle 
mass (31). Inflammation, particularly impaired resolution of inflammation, has 
furthermore been proposed as playing an important role in the pathophysiological 
mechanism behind the development of physical impairment in ICU survivors (32). 
2.1.3 Cognitive impairment in PICS
The cognitive functions most commonly affected after critical illness are memory, 
attention, visual-spatial ability, and executive function (33-35). Cognitive impair-
ment after intensive care is reported in up to 2/3 of survivors, but the prevalence 
varies depending on follow-up time and chosen cognitive tests (13). As with the 
other impairments in PICS, the pathogenesis of cognitive impairment after critical 
illness is still unclear. In part it may be an accelerated neurodegenerative progres-
sion in susceptible patients (e.g., ICU patients are older, might have pre-existing 
cognitive dysfunction and reduced cognitive reserve), or newly obtained brain 
injury due to insults from being critically ill (e.g., hypotension, hypoxia, anemia, 
systemic inflammation, sepsis, pharmacological treatment, renal failure, and liver 
failure) (36-38) (Figure 2).
4Figure 2: Mechanisms and consequences of post-ICU cognitive impairment.  
Modified from (39).
As of today, length of delirium is the only proven independent risk factor for wors-
ened cognitive impairment (6, 7). Other factors previously thought to impact patient 
outcome include the use of benzodiazepines, duration of mechanical ventilation 
or hypo- and hyperglycemia, have, however, shown no, or only weak associa-
tions (7, 40, 41). Additionally, although sepsis in a large retrospective study have 
shown association with the development of cognitive dysfunction (36), traditional 
indicators of disease severity often fail to predict the future severity of cognitive 
impairment (39). As such, the connection between severity of illness and severity 
of impairment remains elusive. 
In addition, assessment of cognitive function after critical illness is challenging, 
since there is a lack of consensus on what, how, and when to test. Most prospec-
tive studies on critically ill patients have not used formal neuropsychological tests. 
Instead, the results are often based on interviews in person, or even by proxy, and 
on tests that were developed to identify Alzheimer’s disease in an elderly population 
(42). This methodology is not optimal to detect mild cognitive impairment, often 
prevalent in ICU survivors. This is important, since even mild cognitive impair-
ment may have significant effects on recovery, particularly in working individuals. 
Furthermore, self-rated screening tools of cognitive function are often interpreted 
as objective measures of cognition (43), a problematic inference given patients’ 
inability to self-assess (44). Conversely, formal neuropsychological testing might 
not reliably indicate problems in everyday life, and both subjective and objective 
measurements may be of equal importance to the patient (45).
2.2 Inflammation, sepsis, and delirium
The immune system comprises the innate and adaptive systems, which together 
act as our body´s defense mechanism against microbial threats and injury (46). 
Infectious products from bacteria (exogenous) and non-infectious products from 
5sterile injury (endogenous) activate the innate immune systems through pattern 
recognition receptors (PRR) (47). The PRRs recognize exogenous products such 
as lipopolysaccharide (LPS) from Gram-negative bacteria and endogenous prod-
ucts such as mitochondrial DNA released from injury. Both microbial products, 
called pathogen-associated molecular patterns (PAMP), and non-microbial prod-
ucts, called damage-associated molecular patterns (DAMP), bind to some extent 
to the same PRRs (48). Four families of PRRs are presently defined: Toll-like 
receptors (TLR), NOD-like receptors (NLR), C-type lectin receptors (CLR), and 
RIG-I like receptors (RLR) (49). Most of the PRRs, when activated, increases the 
production of pro-inflammatory cytokines, leading to a systemic inflammatory 
response (49). This systemic inflammatory response due to exogenous products is 
described clinically as sepsis. However, both sterile and infectious products may 
activate similar immune responses, whether the criteria for a sepsis diagnosis are 
met or not (50, 51).
2.2.1 Sepsis
Sepsis is a life-threatening condition, occurring in more than one-third of ICU 
patients at some point (52). The definition of sepsis has changed over the years 
with the present-day Sepsis-3 criteria (53) being more rigid than the earlier criteria 
developed in 1991 (54). Sepsis survivors have a high short- and long-term mortal-
ity rate and sepsis is associated with a significant burden of morbidity (55, 56). 
This includes multiple organ failure, critical illness myopathy, and acute confusion 
(delirium). Intensive efforts over several decades to develop effective treatment of 
the acute episode have had limited success. The reason for this increased mortality 
and morbidity after primary survival is unclear, but one hypothesis is that post-
septic patients suffer from a phenomenon termed “nonresolving inflammation” (57). 
In critical illness, the systemic inflammatory response can develop into multiple 
organ dysfunction, including brain dysfunction (58). This brain dysfunction is 
not due to infection of the central nervous system (CNS) but instead caused by 
mediators released during sepsis (58). The severity of inflammation impacts its 
influence on cognitive function. In mild cases, systemic inflammation can cause 
minor cognitive changes, and in more severe cases, it may present itself clinically 
as delirium (58, 59).
2.2.2 Delirium
Delirium is an alteration and fluctuation, in attention and cognition that occurs in 
up to 30-80 % of ICU patients (60-63). The occurrence and duration of delirium 
have been independently associated with prolonged hospitalization and increased 
mortality and morbidity (60, 61, 64). Some studies have reported an association 
between sepsis, delirium, and subsequent decline in cognitive function, but it is 
currently unclear whether these clinical symptoms can accurately predict later 
cognitive impairment (6, 7, 36, 40).
6Regarding sepsis-associated delirium, two possible mechanisms have been sug-
gested: sepsis-induced ischemia that leads to inadequate cerebral perfusion and 
inflammatory mediators leading to mitochondrial dysfunction; and microglial and 
endothelial activation, which results in impaired microcirculation, apoptosis and 
the release of neurotoxic substances (65). The endothelial activation plays a central 
part in reduction of the blood-brain barrier (BBB) integrity. Disruption of the BBB 
during sepsis can enable pro-inflammatory factors to enter the CNS, including 
PAMPs and DAMPs. These initiate neuroinflammation through microglia activa-
tion, which is involved in the development of encephalopathy (66). The elevated 
levels of cytokines in the brain that occur during sepsis can induce apoptosis of 
cholinergic neurons. Levels of the neurotransmitter acetylcholine may thus decrease 
and lead to cholinergic hypofunction, which may augment cognitive decline (67). 
2.3 Inflammation and cognitive impairment
Neuroinflammation occurs when the innate immune system is activated within the 
CNS, due to inflammatory signals such as pathogen infection, injury, or trauma. 
Neuroinflammation triggers not only cognitive decline but also behavioral changes, 
described as sickness behavior (68). Sickness behavior includes symptoms of 
lethargy, anorexia, depression, social withdrawal, hyperalgesia, and cognitive 
disturbance (69). Increased levels of cytokines in the CNS have multiple effects, 
including activation of the enzyme indoleamine 2,3-dioxygenase (IDO) involved 
in the Kynurenine pathway (70). The Kynurenine pathway is the central route for 
tryptophan metabolism. IDO promotes the synthesis of Kynurenine, resulting in 
reduced bioavailability of tryptophan, which regulates the rate of serotonin syn-
thesis in the brain and has significant psychological consequences.
ICU-survivors suffer from PICS symptoms such as depression and reduced health-
related quality of life. This may not just be the aftermath of being critically ill. 
Instead, it might be triggered by acute inflammation and further aggravated by 
the non-resolving inflammation. Sickness behavior has also been suggested as an 
important factor contributing to worse self-rated health (69).
The pathophysiology of cognitive dysfunction after critical illness is currently not 
known. Murine studies of experimental sepsis show a link between elevated levels 
of the DAMP high mobility group box 1 (HMGB1) and cognitive impairment in 
murine sepsis survivors. Interestingly, HMGB1 in plasma was elevated for eight 
weeks in mice surviving cecal ligation and puncture (CLP), and this elevation was 
associated with cognitive dysfunction (71). The mice showed problems in learning 
and memory weeks after sepsis, along with reduced hippocampal dendrite density 
and loss of synaptic plasticity (71).  Administration of a monoclonal antibody tar-
geting HMGB1 seven days after CLP abolished the cognitive impairment. In addi-
tion, injection of HMGB1 in healthy mice induced similar pathological changes 
as those found in CLP mice (71) (Figure 3).
7Figure 3: Experimental design in the Chavan et al. study from 2012. In an experimental 
model of sepsis, i.e. cecal ligation and puncture (CLP), in which the cecum is ligated below 
the ileocecal valve and then punctured in anesthetized mice, HMGB1 was associated with 
cognitive impairment.  
2.4 HMGB1
HMGB1, discovered in 1973 as a chromatin-binding molecule, is an evolutionar-
ily highly conserved nuclear protein named for its high electrophoretic mobility 
(72). It is an approximately 25 kDa protein composed of 214 amino acids arranged 
in two DNA-binding domains, the A box and B box, together with a C-terminal 
tail (73). HMGB1 is actively secreted by immune cells in response to pathogenic 
products and injury, or passively released by apoptotic and necrotic cells (Figure 
4). Its role as a prototypical DAMP or alarmin was discovered in 1999, when it 
was found to be elevated in mice during endotoxemia (74). 
In the nucleus, HMGB1’s primary function is to maintain genome stability and 
regulate gene transcription (72). However, when the nuclear localization sequence 
(NLS) of HMGB1 becomes hyperacetylated through posttranslational modification, 
it will translocate to the cytosol (75). Actively released HMGB1 is thus hypera-
cetylated, whereas HMGB1 passively released from dying or injured cells is not. 
The active secretion from the cytosol to the extracellular milieu is not entirely 
understood, as HMGB1 lack a secretory leading peptide and is therefore not 
transported through the classical endoplasmic reticulum-Golgi pathway. Instead, 
HMGB1 seems to be accumulated in secretory lysosomes from where it can be 
released into the extracellular milieu in response to inflammatory signals (76). 
7KLVV\VWHPLVVLPLODUWRKRZRWKHUSURLQIODPPDWRU\F\WRNLQHVVXFKDV,/ȕ
are released, which is rapidly secreted from lysosomes in response to extracel-
lular ATP that is high in inflammatory conditions (78). However, the exocytosis 
of HMGB1 is different as it is induced by lysophosphatidylcholine (LPC), a lipid 
that is produced by immune cells, usually at the site of infection (76).
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Figure 4: a) HMGB1 bends DNA in the nucleus and modulates interaction of transcrip-
tion factors with DNA. b) HMGB1 induces cell migration and promotes axonal growth at 
the cell surface. c) HMGB1 binds to RAGE, TLR 2 and 4 and signals through NF-kB d) 
HMGB1 is actively secreted by immunocompetent cells e) HMGB1 is passively released 
during necrosis f) HMGB1 sequestered in the nucleus after apoptosis (77). Reprinted with 
permission from publisher.
In the extracellular milieu, HMGB1’s function to regulate inflammation is depend-
ent on the redox state of cysteine residues at position 23, 45, and 106 (79). This 
redox state is variable and to a great extent depending on the redox balance in the 
intra-and extracellular milieu. When the three cysteine residues are in their fully 
reduced form with thiol residues, the complex is inactive, as is the state of nuclear 
HMGB1. Oxidation of HMGB1 creates a disulfide bond between Cys 23 and Cys 
45, causing it to switch into a potent pro-inflammatory cytokine (80). When fully 
oxidized, HMGB1 is in its irreversible sulfonyl form, which has no known immu-
nologic function (80). Receptors that mediate HMGB1 signaling include receptor 
for advanced glycation end products (RAGE), TLR 2, -4, and -9, among others, 
where TLR-4 is the primary receptor for macrophage activation and cytokine 
release (81). The redox state of HMGB1 regulates its ability to bind to the differ-
HQWUHFHSWRUV)LJXUH7/5DFWLYDWHVWKH1)ț%SDWKZD\WKURXJK0\'
DQLQWUDFHOOXODUDGDSWRUSURWHLQWKDWFDQDFWLYDWHWKHWUDQVFULSWLRQIDFWRU1)ț%
(82). 1)ț%DFWLYDWLRQSURPRWHVWKHWUDQVFULSWLRQRISURLQIODPPDWRU\F\WRNLQHV
and chemokines (chemoattractant cytokines) in several cell types, including 
9 macrophages, mast cells, and endothelial cells (82). Central cytokines in inflam-
PDWLRQLQYROYHWXPRUQHFURVLVIDFWRUĮ71)ĮLQWHUOHXNLQȕ,/ȕDQG,/
which are usually produced locally, at the site of infection. However, cytokines, 
DAMPs, and PAMPs may enter the circulation and induce a systemic inflam-
matory response, which often occurs in infection or inflammatory diseases (83). 
HMGB1, in the extracellular milieu, is prone to synergize and form complex 
with several other pro-inflammatory molecules, including DNA, RNA, histones, 
QXFOHRVRPHV/36&;&/,/ĮDQG,/ȕ7KLVPROHFXODUFROODERUD-
tion is an important mechanism for HMGB1-mediated inflammation (85-87). 
Extracellular HMGB1-partner molecule complexes bind to RAGE on cell surfaces 
and become endocytosed to the endolysosomal compartment. HMGB1 then acts 
as a detergent under the acidic conditions in lysosomes, where HMGB1 disrupts 
the lysosomal membrane and enables its partner molecules to avoid degradation 
and to escape to the cytosol to activate reciprocal intracellular receptors (84, 85). 
One essential example of this mechanism is that LPS-toxicity in sepsis involves 
HMGB1-assisted transport (85). When LPS enters the cytosol through HMGB1-
RAGE-mediated entrance and avoids degradation, it will intracellularly activate 
Caspase-11, which in turn cleaves Gasdermin D into peptides that create pores in 
the cytoplasmic membrane (88, 89) (Figure 6). This process is called pyroptosis 
(“pyro” from greek “fire”) and is a highly inflammatory form of programmed 
cell death (90). One major source of HMGB1-release in experimental sepsis is 
hepatocytes (85). Experimentally, deletion of HMGB1 in hepatocytes, neutraliz-
ing extracellular HMGB1, loss of caspase-11, or deficiency in Gasdermin-D, all 
independently improved survival in mouse models of sepsis (85, 91).
In summary, HMGB1´s function depends on its location, molecular binding 
 partners, and redox state (92).
Activation of the systemic inflammatory response is also regulated through the brain 
stem and the neural circuits of the vagus nerve (93). Sensory nerve fibers report 
on cytokine levels and inflammation in the periphery, and signals to the brain via 
the afferent vagus nerve. The brain stem processes this information, which acti-
vates the efferent vagus nerve to inhibit the release of pro-inflammatory cytokines 
through the “inflammatory reflex arc” (93). Activation of this anti-inflammatory 
reflex results in the activation of adrenergic neurons in the spleen that promotes 
VSOHQLF7FHOOVWRUHOHDVHDFHW\OFKROLQH$FHW\OFKROLQHELQGVWRĮQLFRWLQLF
DFHW\OFKROLQHUHFHSWRUVXEXQLWĮQ$&K5RQPRQRF\WHVPDFURSKDJHVDQGLQKLELWV
the release of pro-inflammatory cytokines (96, 97) (Figure 7). Interestingly, this 
neural circuit also regulates inflammasome activation and serum HMGB1 levels 
(98, 99). This is particularly interesting in light of the potential therapeutic use of 
selective nerve stimulation in treatment of excessive inflammation (100).
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Figure 5: The different redox forms of HMGB1 regulate receptor binding. All-thiol 
HMGB1 (atHMGB1) forms a complex with CXCL12 that signals via CXCR4 and have 
chemotactic properties. Disulfide HMGB1 (dsHMGB1) signals via TLR4 with pro- 
inflammatory effects. AtHMGB1, dsHMGB1 and sulfonyl HMGB1 (oxHMGB1) all bind 
to RAGE (84). Reprinted with permission.
Figure 6: Extracellular HMGB1-partner molecule complexes bind to cell surface-
expressed RAGE and become endocytosed to the endolysosomal compartment. HMGB1 
then acts as a detergent under the acidic conditions in lysosomes, where HMGB1 disrupts 
the lysosomal membrane, enabling LPS to avoid degradation and to escape to the cytosol 
to activate Caspase-11. Caspase-11 then cleaves Gasdermin-D into peptides that create 
pores in the cell membrane, and pyroptosis occurs. (Copyright: Ulf Andersson)
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2.4.1 HMGB1 in neuroinflammation
HMGB1 plays a central role in promoting neuroinflammation through activa-
tion of microglia, the predominant innate immune cell in the brain (101, 102). 
Microglia express TLRs, in particular TLR4, one of HMGB1s main receptors 
(103), and activation of microglia with elevated systemic HMGB1 levels have 
in experimental models correlated with cognitive dysfunction (104). HMGB1 is 
also capable of disrupting the blood-brain barrier and thus enables entry of other 
pro-inflammatory mediators, further aggravating the inflammation (105, 106). In 
addition to TLR-4 and RAGE, the N-methyl-D-aspartate receptor (NMDA-rec) 
is important in HMGB1 mediated neuroinflammation. NMDA-rec are known to 
regulate neurotransmission, but also synaptic plasticity, learning, memory, and 
cognition (107). HMGB1 have pro-excitatory effects on the NMDA-rec in the 
hippocampus through increased phosphorylation of the receptor and, therefore, 
calcium channel conductance (108). 
HMGB1´s function in neuroinflammation has been extensively studied in differ-
ent disease models, including traumatic brain injury (109), ischemic brain lesions 
(110), epilepsy (111), Alzheimer´s disease (112), stress (67), and depression (113). 
Figure 7: Signals in efferent vagal neurons 
functionally activate adrenergic nerve terminals 
in the spleen to release norepinephrine, which 
promotes acetylcholine release from choline 
acetyltransferase (ChAT)+ T cells. Acetylcholine 
ELQGVWRĮQ$&K5RQPDFURSKDJHVDQGVXS-
presses synthesis and release of pro-inflammatory 
F\WRNLQHVHJ71)Į,/,/DQGRWKHUV
(Copyright: Laura Tarnawski)
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Furthermore, HMGB1 has been shown to cause hippocampal inflammation and 
cognitive impairment in both experimental sepsis and major sterile trauma in mice 
(71, 102, 114-117). Collectively, these observations support a functional role of 
HMGB1 in the development of neuroinflammation and cognitive impairment, 
both in sepsis and sterile inflammation. 
As mentioned earlier, many studies targeting a number of pro-inflammatory media-
tors have shown great promise in attenuating sepsis in murine models. However, 
clinical trials built on these experimental discoveries have ultimately failed (118-
120), and ever since pro-inflammatory cytokines were found to be elevated in 
patients with severe infection (121), the focus has been on finding therapy target-
ing this response. A vital difference between HMGB1 and other pro-inflammatory 
cytokines is that it is a late mediator of inflammation (74). In contrast to other 
F\WRNLQHVUHOHDVHGLQVHSVLVVXFKDV71)Į,/DQG,/ZKLFKUHWXUQEDFN
to baseline levels within hours after sepsis onset, HMGB1 may stay elevated for 
weeks after an acute event (122-124). This difference is important, as it gives a 
wider therapeutic time window to administer treatment. Administration of antago-
nists of HMGB1 to mice, e.g. monoclonal antibodies or recombinant HMGB1 box 
A protein, up to 24 h after disease onset significantly improved survival (125). 
Moreover, monoclonal anti-HMGB1 antibodies administrated to mice 6, 9, and 
11 days after CLP, as described in the Chavan et al. study, significantly improved 
memory function (71). This suggests a possibility of great clinical importance 
and a promising new potential molecular target for therapy in severe systemic 
inflammation (80).
2.4.2 HMGB1 in muscle dysfunction
Cytokines and other mediators of inflammation play essential roles in the regula-
tion of skeletal muscle through their effects on metabolism, protein turnover, and 
cell differentiation (126). A key feature in ICU-acquired weakness is the loss of 
myosin filaments and the disruption of the myofilament organization of the tissue 
$FWLYDWLRQRIWKH1)ț%SDWKZD\ZLOOLQFUHDVHQRWRQO\WKHSURGXFWLRQRI
pro-inflammatory cytokines, but also the expression of ubiquitin–proteasomes that 
are involved in muscle-specific atrophy (128), and as mentioned earlier, HMGB1 
DFWLYDWHVWKH1)ț%SDWKZD\)XUWKHUPRUHH[SHULPHQWDOGDWDLQGLFDWHWKDW+0*%
impairs muscle Ca2+ homeostasis by HMGB1 signaling through TLR4 (129), and 
that RAGE, the other main receptor of HMGB1 has found to be involved in skel-
etal muscle turnover (130).  However, little is known about the long-term course 
of inflammation and its association with physical impairment in ICU survivors. 
Considerable challenges lay ahead in both the field of PICS and HMGB1 biology. 
The complexity and heterogeneity of the ICU population, together with the lack 
of baseline data in this patient group due to acute admission, thwarts progress. 
The studies presented in this thesis will, hopefully, shed some small light on the 
mechanisms behind the impairments in post-intensive care syndrome.
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3 AIMS
Study I: (a) To examine the relationship between sepsis, ICU delirium, and later 
self-rated cognitive function in ICU survivors. 
(b) To investigate the association between depression, anxiety, PTSD, and  self-rated 
cognitive function after ICU stay.
Study II: To investigate if subjective cognitive function correlate to objective 
 cognitive function as measured by Cambridge Neuropsychological Test Automated 
Battery (CANTAB) in ICU survivors.
Study III: To investigate plasma HMGB1 levels in ICU survivors, and if elevated 
plasma HMGB1 levels are associated with cognitive dysfunction as measured by 
neuropsychological tests (CANTAB).
Study IV: To examine if plasma HMGB1 levels are associated with physical 
performance in ICU survivors.
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4 METHODS
4.1 Ethical considerations
The Stockholm regional ethics committee approved studies I-IV, which were 
conducted in accordance with the Helsinki declaration (131), and good clinical 
practice. All patients included in the studies gave written informed consent. In 
order to protect patients’ autonomy, we emphasized that participation was entirely 
voluntary, and patients had the opportunity to cancel their participation at any 
time. Blood samples were taken through existing vascular access at the hospital, 
and at two time-points during follow-up. The risk of inflicting harm on the study 
patients was considered minimal. In studies II-IV, the follow-up offered was more 
thorough compared to standard care, and patients may have benefitted from this. 
4.2 Description of studies
Detailed descriptions of the method can be found in the method section in the 
respective papers.
4.2.1 Study I
In this prospective cohort study, data were collected from January 2012 until 
February 2013.  Part of the patients was included in an international multicenter 
study (PRE-DELIRIC) (132). Eligible for inclusion were patients staying longer 
than 24 hours at the ICU. Patients who were mentally impaired, had severe auditory 
or visual disorders, suffered from aphasia, were unable to understand Swedish, or 
were transferred to another ICU were excluded. Patients that were sedated during 
their entire ICU stay and had a Richmond Agitation and Sedation Scale of minus 
four or less were also excluded.
Patients were screened for delirium daily at the ICU using the Confusion Assessment 
Method for the ICU (CAM-ICU) (133), and their sepsis status was noted. In this 
study, we diagnosed patients with the standard definitions used at the time of patient 
inclusion (Table 1). As sepsis without any organ dysfunction is commonly found 
in the ICU, we chose patients with severe sepsis and septic shock to be defined as 
one group, in order to distinguish patients more affected by their infection. 
Study participants received three questionnaires by postal mail; CFQ (measures 
self-rated cognitive function) (134), HADS (measures anxiety and depression) (135), 
PTSS-10 (measures symptoms of post-traumatic stress) (136), three months after 
their ICU discharge.  Independent variables of the study were sepsis or delirium at 
the ICU, and depression, anxiety, and PTSD at the follow-up. The outcome vari-
able was patients’ self-rated cognitive function measured by the CFQ at follow-up.
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Clinical definitions of sepsis
Systemic inflammatory response 
syndrome (SIRS)
Two or more of the following
• Temperature >38°C or <36°C
• Heart rate >90/min
• Respiratory rate >20/min
• White blood cell count >12x109 or <4x109
Sepsis SIRS and evidence of infection
Severe sepsis At least one sign of sepsis associated organ dysfunction, 
hypoperfusion or hypotension, including lactate acidosis, 
oliguria, or acute alteration of mental state
Septic chock Severe sepsis with hypotension (systolic blood  pressure 
<90mmHg or a reduction from baseline >40mmHg) 
refractory to adequate fluid resuscitations or need of 
 inotropic drug
Table 1: Clinical definitions of sepsis used at the time of study inclusion. 
4.2.2 Study II-IV
Data were prospectively collected from May 2014 to January 2018 for study 
II-IV. Patients staying more than 24 hours and aged 18-70 were included. In order 
to recognize patients who were cognitively intact before admittance to the ICU, 
narrow exclusion criteria were used. This included patients with severe auditory 
or visual disorders, aphasia or inability to understand Swedish, diagnosed with 
mental impairment or dementia, ongoing alcohol or drug abuse, psychiatric ill-
ness and/or psychiatric pharmacological treatment. Further, to identify patients 
with undiagnosed pre-existing dementia, the Short Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) (137) was used to screen all patients 
above 50 years of age, where patients with a high score (i.e. >3) were excluded. 
Additionally, patients receiving extracorporeal membrane oxygenation (ECMO), 
patients diagnosed with meningitis, patients with structural brain injury, patients 
in palliative care, or patients unlikely to survive to follow-up (3 months) were 
also excluded. Patients with an ICU stay of less than 48 hours were excluded as 
a short ICU stay may have less of an impact on the outcome. Patients transferred 
to another ICU or patients residing outside Stockholm were also excluded, as 
follow-up would not have been feasible.
Patient characteristics and medical data form ICU stay (i.e. APACHE II, SAPS III, 
presence of delirium, sepsis status, mechanical ventilation) were obtained from 
the electronic management data system (Take Care, Clinisoft). In study III, we 
diagnosed patients according to the Sepsis-3 criteria (Table 2) (53, 138). 
For study III, blood samples were collected during hospital stay, and at three and 
six months after ICU discharge. For study IV, the same measurement was used at 
the three and six month follow-up. In study III, plasma was also obtained from 22 
healthy subjects from Sweden and used as a reference group for HMGB1 (139).
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Sepsis-3
Sepsis Evidence of infection and an increase in SOFA score >2
Septic chock Sepsis with hypotension that despite fluid resuscitations 
UHTXLUHLQRWURSLFGUXJWRPDLQWDLQ0$3PP+JDQG
lactate > 2 mmol/L
Table 2: Criteria for Sepsis-3. The Sequential Organ Failure Assessment (SOFA) score is 
calculated from severity of illness in six organ systems; respiratory (PaO2/FiO2), hepatic 
(bilirubin), cardiovascular (blood pressure and vasopressors), coagulation (platelets), cen-
tral nervous system (Glasgow coma scale), and renal system (creatinine and urinary output)
 
Patients came to the follow-up clinic for intensive care at three, six, and twelve 
months after ICU discharge (Figure 8). They there performed formal neurophysi-
ological testing assessed with the CANTAB (CANTAB® [Cognitive assessment 
software], Cambridge Cognition (2013)). Four different cognitive tests from 
the CANTAB battery were chosen to measure executive function (Stockings of 
Cambridge (SOC)), working memory (Spatial span (SSP)), visual memory (Pattern 
recognition memory (PRM)) and sustained attention (Rapid visual information 
processing (RVP)) (Table 3). Patients also performed three physical tests; the 6-min 
walk test (6-MWT), the handgrip-strength test (HST), and the timed stands test 
(TST) to measure physical performance. Along with the cognitive and physical 
tests, they handed in three questionnaires that measure self-rated cognitive function 
(CFQ), symptoms of anxiety and depression (HADS), and PTSS-10 that measures 
symptoms of posttraumatic stress.
Figure 8: Study design of study II-IV.
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In study II, was the correlation between the outcome variable CFQ and the vari-
ables of the four different CANTAB tests over the 12-month follow-up measured. 
The independent variable in study III was plasma HMGB1 levels and the outcome 
variable the score on the four different chosen CANTAB tests (i.e SOC, SSP, PRM, 
RVP) from the three and six-month follow-up. 
In study IV, the independent variable was HMGB1 plasma levels at three and six 
months and the outcome variable the score on the three physical tests (6-MWT, 
HST, and TST) at the same time-points.
Test chosen Area Function
Pattern recognition memory (PRM) Temporal Visual memory
Spatial Span (SSP) Frontal, Hippocampal Working memory
Stockings of Cambridge (SOC) Frontal Executive functioning
Rapid visual information processing (RVP) Frontal and parietal Sustained attention
Table 3: Chosen CANTAB test for neuropsychological testing, which area of the brain 
that is involved and what function they test.
4.3 Measurement of HMGB1
Blood samples were centrifuged at +4 °C for 10 minutes, at 1000g within 30 min 
from collection. Plasma was stored at -80 °C for later analyses. Plasma HMGB1 
concentrations in ICU survivors and healthy subjects were measured using an 
enzyme-linked immunosorbent assay (Shino-test HMGB1 ELISA, #ST51011; 
IBL International, Hamburg, Germany) according to the manufacturer instructions.
4.4 Statistics
Numeric variables were summarized with medians and interquartile ranges 
and absolute and relative frequencies were reported for categorical variables. 
Questionnaire data were treated as ordinal. 
In study I, the association between ICU delirium and severe sepsis/septic shock 
was analyzed using logistic regression with crude and adjusted (adjusted for; 
APACHE II score, diabetes mellitus, substance abuse, history of psychological 
problems) odds ratio calculated. Generalized estimating equations was used in study 
I assessing the association between severe sepsis/septic shock, ICU delirium, and 
later self-rated cognitive function (CFQ) and presented as mean differences with 
95 % CI. The possible combined effect of sepsis and delirium on CFQ scores in 
study I was analyzed using Kruskal-Wallis one-way analysis of variance.
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Spearman’s rank correlation was used in study I and II when analyzing the correla-
tion between psychological distress (HADS and PTSS-10) and self-rated cognitive 
function (CFQ), and in study II analyzing correlation between subjective (CFQ) 
and objective (CANTAB) cognitive function, rendering the Spearman correlation 
coefficient known as rho or r.
Linear mixed models were used in study II-IV with a patient-specific random inter-
cept included in all models to account for intra-patient correlations. Fixed factors 
included in the model of study III entails the logarithm of HMGB1, age, gender, 
education level, and the effect of time. In study IV the logarithm of HMGB1, age 
and gender were includes as fixed factors. HMGB1 was log-transformed using 
the natural logarithm to handle skewness. Pairwise deletion was performed to 
handle missing data. 
The sign test was used in study III to compare the z-score median of our cohort 
compared to British normative data provided by the CANTAB company.
Stata versions 14 and 15 (StataCorp, College Station, TX, USA) and GraphPad 
Prism version 6 (GraphPad Software, San Diego, CA, USA) were used for statis-
tical analyses, and p-values <0.05 were considered significant.
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5 RESULTS
5.1 Study I
A total of 754 patients were screened, 514 excluded, and 20 patients died before 
follow-up, resulting in 216 patients receiving the questionnaires three months 
after ICU discharge. Of those, 60 % (N=125) of the patients responded to all three 
questionnaires.
Patients with severe sepsis or septic shock at the ICU were more prone to develop 
ICU delirium with a crude OR of 3.7 (95% CI, 1.7–8.1), and adjusted OR of 2.9 
(95% CI, 1.2–7.2) (adjusted for APACHE II score, diabetes mellitus, history sub-
stance abuse, or history of psychological problems) (Figure 9). 
No severe sepsis
0
50
100
Severe sepsis/Septic shock
%
 o
f p
at
ie
nt
s
No delirium
Delirium
Figure 9: The incidence of delirium was significantly higher in patients with severe sepsis/
septic shock with an adjusted odds ratio of 3.7 and 95% confidence interval of 1.7-8.1.
There was no significant association between CFQ scores for patients with delirium 
or severe sepsis/septic shock or those without (Table 4). We also investigated the 
possible interaction of sepsis and delirium on CFQ scores without significant 
findings (Figure 10)
20
Cognitive failure questionnaire score
Crude model 
0'&,
Adjusted model* 
0'&,
No severe sepsis/septic 
shock (reference)
 
0
 
0
Severe sepsis/septic shock WR WR
Delirium WR WR
Table 4: Mean differences (MD) in CFQ score and 95% confidence intervals. No severe 
sepsis/septic shock was set as a reference. There was no significant difference between 
groups using generalized estimations equations.
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Figure 10: Patients´ individual CFQ score at three months is plotted divided in four 
groups based on the presence of delirium or severe sepsis/septic shock at ICU stay. Lines 
represent median and whiskers the interquartile range. ns = not significant. 
Scores on PTSS-10 and HADS both significantly correlated with the CFQ scores, 
i.e. patients with more symptoms of depression, anxiety, and PTSD had worse self-
rated cognitive function at three months after ICU discharge (r = 0.44-0.53 p < 0.001).
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5.2 Study II
The flowchart of patient participation is shown in Figure 11. Patient characteristics 
are shown in Table 5. As measured by the four selected CANTAB tests, cognitive 
impaired was present in 34 % at three months, 18 % at six months, and 16 % of 
patients at twelve months after discharge in this cohort. There were no significant, 
nor any clinically relevant correlation between patients’ subjective score on the CFQ 
and their cognitive performance as measured by the four different CANTAB tests 
using Spearman’s rank correlation (3 months r=-0.134-0.207, p>0.05, at 6 months 
r=-0.106-0.257, p>0.05, and at 12 months after discharge r=-0.070-0.109, p>0.05) 
(Figure 12). In line with study I, there was a significant correlation between 
psychological distress and patients’ self-rated cognitive function (r=0.372-0.710, 
p=<0.001-0.023) throughout the follow-up period (Figure 13). 
Screened patients - n=917
Excluded patients - n=817
Included at ICU - n=100
Deceased before follow-up - n=19
Declining participation - n=16
Excluded before follow-up - n=7
Patients lost to follow-up - n=7
Deceased before follow-up - n=2
Patients lost to follow-up - n=4
3-month follow-up - n=58
6-month follow-up - n=51
12-month follow-up - n=45
 Figure 11: Flowchart of patient follow-up.
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Follow-up cohort at 
3-months (N=58)
Age - yr, median (IQR)  
Male sex - no. (%)  44 (76)
Level of education - no (%) Primary 
Secondary 24 (41)
Tertiary 19 (33)
Nicotine abuse - no. (%)  22 (38)
Comorbidity - no. (%) Cardiovascular 18 (31)
Respiratory 7 (12)
Gastrointestinal 
Diabetes 6 (10)
Cancer 8 (14)
Immunological 2 (3)
Neurological 4 (7)
APACHE II score - median (IQR)  26 (22-30)
SAPS III score - median (IQR)  
Sepsis/septic chock (Sepsis 3) - no. 
(%)  42 (72)
Mechanical ventilation - no. (%)  44 (76)
Delirium - no. (%)  17 (29)
Duration of ICU stay - days, median 
(IQR)  
Table 5: Patient characteristics. IQR, interquartile range; APACHE, Acute Physiology and 
Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; Level of education, 
according to the Swedish national school system (Primary – ages 6-15, Secondary – ages 
15-18, Tertiary – University level).
23
Fi
gu
re
 1
2:
 C
or
re
la
tio
n 
be
tw
ee
n 
su
bj
ec
tiv
e a
nd
 o
bj
ec
tiv
e c
og
ni
tiv
e f
un
ct
io
n.
 In
di
vi
du
al
 p
at
ie
nt
s s
co
re
 a
re
 p
lo
tte
d 
A)
 C
FQ
 sc
or
es
 a
nd
 %
  co
rr
ec
t 
on
 th
e 
PR
M
 te
st
 B
) C
FQ
 sc
or
es
 a
nd
 th
e 
ou
tc
om
e 
m
ea
su
re
 R
VP
 A
’ C
) C
FQ
 sc
or
es
 a
nd
 n
um
be
r o
f t
es
ts
 w
ith
 m
in
im
um
 m
ov
es
 c
om
pl
et
ed
 in
 th
e 
SO
C
 te
st
 D
) C
FQ
 sc
or
es
 a
nd
 sp
an
 le
ng
th
 a
ch
ie
ve
d 
on
 th
e 
SS
P 
te
st
 
24
F
ig
ur
e 
13
: C
or
re
la
tio
n 
be
tw
ee
n 
su
bj
ec
tiv
e 
co
gn
iti
ve
 fu
nc
tio
n 
an
d 
ps
yc
ho
lo
gi
ca
l d
is
tr
es
s. 
In
di
vi
du
al
 p
at
ie
nt
s 
sc
or
e 
ar
e 
pl
ot
te
d 
A)
 
C
FQ
 s
co
re
s 
an
d 
H
AD
S 
an
xi
et
y 
su
bs
ca
le
 s
co
re
 B
) C
FQ
 s
co
re
s 
an
d 
H
AD
S 
de
pr
es
si
on
 s
ub
sc
al
e 
sc
or
e 
C
) C
FQ
 s
co
re
s 
an
d 
PT
SS
-1
0 
sc
or
e.
 
C
FQ
, T
he
 C
og
ni
tiv
e 
Fa
ilu
re
s 
Q
ue
st
io
nn
ai
re
; C
AN
TA
B,
 C
am
br
id
ge
 N
eu
ro
ps
yc
ho
lo
gi
ca
l T
es
t A
ut
om
at
ed
 B
at
te
ry
; P
RM
, P
at
te
rn
 R
ec
og
ni
tio
n 
M
em
or
y;
 R
VP
, R
ap
id
 V
isu
al
 In
fo
rm
at
io
n 
Pr
oc
es
sin
g;
 S
O
C,
 S
to
ck
in
gs
 o
f C
am
br
id
ge
; S
SP
, S
pa
tia
l S
pa
n;
 H
AD
S,
 H
os
pi
ta
l A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 P
TS
S-
10
, P
os
t-t
ra
um
at
ic
 S
ym
pt
om
 S
ca
le
.
25
5.3 Study III
Flowchart and patient characteristics are shown in Figure 11 and Table 5. Plasma 
levels of HMGB1 were significantly elevated in ICU survivors, compared to 
a healthy reference group (Figure 14a). Other investigated proinflammatory 
F\WRNLQHVLQFOXGLQJ71)Į,/ȕ, IL-6, IL-8, IL-12p70, and IL-10, were not 
elevated at three months after ICU discharge (N=18, data not shown).  The evo-
lution of HMGB1 levels differed between patients as shown in Figure 14b, and 
plasma HMGB1 levels increased in the majority of patients between the three- and 
six-month follow-up visits. 
Figure 14: a) Plasma HMGB1 levels 
over the follow-up period. In healthy 
controls 2.0±1.4 ng/mL (N=22). 
In ICU survivors, 6.1±3.6 ng/mL 
(N=56), at ICU-discharge 8.6±4.3 
ng/mL (N=50), at three months 
after ICU discharge 11.3±9.4 ng/mL 
(N=56), and at six months 11.7±6.3 
ng/mL (N=43). Numbers indicate 
mean plasma HMGB1 values ± stand-
ard deviation. Individual values are 
plotted.  
****- p<0.0001.  
b) Patients individual evolution of 
plasma HMGB1 levels. Different 
colors and lines represent individual 
patients.
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Patients’ z-score derived from gender and age-matched British normative data 
provided by the CANTAB manufacturer, show a significant reduction in their per-
formance on the RVP test that measure sustained attention at both three (p<0.0001) 
and six months (p=0.04) (Figure 15 a, b). RVPA’ test score also significantly 
improved between three and six months (p=0.01), whereas there is no significant 
change regarding the other tests (SSP, SOC, PRM).
Figure 15: Patients individual z-score at a) three months and b) six months after ICU 
discharge. The median z-score of the tests is indicated by red lines. Patients´ individual 
z-score is plotted. PRM, pattern recognition memory (% correct); RVP, rapid visual infor-
mation processing (RVPA’); SOC, Stockings of Cambridge (min moves); SSP, spatial span 
(span length). 
27
Plasma levels of HMGB1 at three and six months were significantly associated with 
RVPA’ scores, i.e. an increase in plasma HMGB1 was associated with a decrease 
in RVPA’ score (Figure 16) both crude (p=0.03) and after adjusting for age, gender 
and education level (p=0.02). There was no significant association between plasma 
HMGB1 levels and the test scores on the other cognitive tests (SOC, PRM, SSP).
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Figure 16: HMGB1 and sustained attention in linear mixed models adjusted for age, 
gender, and education level. Log transformed HMGB1 levels at three and six months on 
the x-axis and RVPA’ score at three and six months on the y-axis. Individual patient values 
are plotted. R2=0.21, p=0.02. RVP, rapid visual information processing
5.4 Study IV
Flowchart and patient characteristics are found in Figure 11 and Table 5. Patients’ 
physical performance significantly improved over the follow-up period (p<0.01-
0.02). There was no significant association between plasma HMGB1 levels and 
physical performance at follow-up (Table 6). Patients performed worst on TST 
and HST compared to the reference values (Table 7), and 16 % of patients under-
performed on all tests at three months, and 12 % at six months.
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Physical tests Coef. 95 % CI p-value
Handgrip strength right
       HMGB1 (3+6 months)
       Time (6 months)a
 
- 0.46
1.79
-2.36-1.43

0.63
0.02
Handgrip strength left
       HMGB1 (3+6 months)
       Time (6 months)a

1.29

-0.42-3.00

0.14
Timed stands test
       HMGB1 (3+6 months)
       Time (6 months)a
-0.39
-3.84
-3.33-2.21
-6.39-1.28
0.69
<0.01
6-min walk test
       HMGB1 (3+6 months)
       Time (6 months)a
12.4
42.0
-23.9-48.6


<0.01
Table 6: Plasma HMGB1 levels and physical test scores. Plasma HMGB1 levels and 
physical performance at three and six months were analyzed in a linear mixed model 
adjusted for age and gender. Time (6 months) shows the effect of time on the specific test. 
a = reference 3 months
Number of patients with reduced physical  
performance score
Follow-up at 3-months Follow-up at 6-months
6-min walk test - no. (%) 17 (31) 
Handgrip-strength test right - no. (%)  16 (32)
Handgrip-strength test left - no. (%) 17 (30) 16 (32)
Timed-stands test - no. (%)  23 (46)
Under performed at all tests – no. (%) 9 (16) 6 (12) 
Table 7: Number of patients with reduced physical performance at the three and six 
month follow-up. Reduced physical performance was defined as scoring below the 95% 
confidence interval in age and sex adjusted reference values. 
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6 DISCUSSION
6.1 Methodological considerations
6.1.1 Validity
The applicability of epidemiological studies depends on its internal and external 
validity. Internal validity is defined as to what degree observations are correct and 
not due to methodological errors or confounding factors, i.e. that the results found 
in a study represent the truth. External validity represents the generalizability to 
which the result found in a study can be applied to other study populations. If a 
study lacks internal validity, external validity becomes irrelevant. 
The validity is influenced by sources of errors frequently found in epidemiological 
studies and consists of systematic and random errors. Systematic errors include 
selection bias, misclassification, and confounding. 
Selection bias occurs when the selection of the study population creates the impres-
sion that two variables are related even though they are not associated in the target 
population. In cohort studies where data is collected prospectively, inclusion and 
exclusion is not based on future outcomes, which reduces the risk of selection 
bias. However, in follow-up studies, there is a risk of the unhealthy survivors 
(i.e. those with most problems die or are unable to participate in follow-up) and 
healthy survivors (i.e. those with no problems resume to normal life and work, and 
therefore do not attend follow-up or send back questionnaires) bias. This selection 
bias could be present in study I-IV as all are follow-up studies. 
Misclassification or information bias occurs when exposure or outcome are inac-
curately recorded. These misclassifications can appear equally (non-differential) 
or not equally (differential) between groups in a study. The definition of sepsis 
and diagnose of delirium in study I and III are both liable to misclassification. 
Confounding is one of the major threats to internal validity in epidemiological 
studies. This occurs when a factor that is independently associated with both the 
exposure and outcome affect the association. Confounders can be handled through 
randomization, restriction, and matching. It is also possible to adjust in statistical 
analysis for potential known confounders through stratification or multivariate 
analysis. In study I-IV, strict exclusion criteria were set to limit the influence of 
potential confounders. Adjustments for confounders in the statistical analysis were 
also made in study I-IV. We cannot, however, as with any observational study, 
rule out the risk of bias due to unmeasured confounders. 
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Even when a study is perfectly designed and systematic errors are minimized, 
there will always be a risk of chance findings. These results are always unknown, 
unpredictable, and referred to as random errors. In study I-IV, we set a signifi-
cance level of p<0.05, with a 5 % risk of type I errors, i.e. finding an association 
or difference where there is none. The relatively small sample sizes of the stud-
ies conducted here also give an inherent risk of type II errors, i.e. not finding an 
association or difference when there is one.
In summary, given the strict study design of the studies conducted here, a higher 
internal validity may be assumed. The external validity or generalizability should, 
however, be interpreted with caution, considering that it is single-center studies, 
with relatively small sample sizes, from a general ICU with a high proportion of 
trauma patients, which results in a relatively young study population and a higher 
proportion of men. 
6.1.2 Self-assessment
Self-evaluation is difficult, and there are several pitfalls that people tend to succumb 
to when they assess their abilities. One may presume that self-assessment should 
be unbiased and closely connected to our genuine abilities as we are continuously 
given real-life information on how we perform various tasks. Nevertheless, many 
studies have found our ability to self-assess to be biased, especially when it comes 
to self-estimating functions such as cognitive ability (44). The main distortion in 
self-assessment is the better-than-average effect, which is defined as the tendency 
of individuals to assess various abilities as being above average (140). Another 
well-known bias is the Dunning-Kruger effect that focuses on differences in meta-
cognition (i.e. being aware of one’s awareness). It includes the fact that people who 
generally overperform, underestimate their ability and those who underperform, 
overestimate theirs (141). Furthermore, regarding CFQ that was used in study 
I and II, there is also an age-CFQ paradox, where older people that have more 
cognitive impairments rate themselves with low (i.e. less cognitive difficulties) 
score. In order to answer the CFQ, one needs to remember what one has forgotten, 
something that is difficult in those cognitively worse off (142). This is an inherent 
methodological problem with this type of self-rated cognitive ability assessment 
tools, leading to misidentification of cognitive impairments by self-rated screen-
ing tools. In addition, there is also a “complaint hypothesis” when assessing both 
cognitive and psychological problems (143). If a patient feels a need for help, 
no matter the reason, they increase their symptoms when self-evaluating, some-
thing that is common in clinical follow-up, where the score on the different tests 
determines the need for intervention. In both cognitive and mental impairments, 
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a discrepancy between the individuals’ self-perception and the actual deficits the 
clinician intends to assess may result in misjudge of the need for rehabilitation, 
or the risk of early termination of rehabilitation although needed, in both cases 
with negative consequences for patients’ recovery. Structured, unbiased screening 
tools are, therefore, of great importance in ICU follow-up.
6.1.3 HMGB1
To increase the reproducibility and allow for comparison, the use of reliable meth-
ods for detecting HMGB1 is essential. We measured HMGB1 with the current 
gold standard ELISA from Shino-test Corporations (144). Several studies have 
instead used western blot, a method that has its limitations in the quantification of 
HMGB1 concentrations. As mentioned in the introduction, HMGB1 can complex-
bind with several other pro-inflammatory cytokines. The ELISA form Shino-test 
Corporations uses acidic buffers, to promote dissociation to bound molecules 
from HMGB1. In western blot targeting HMGB1, a filter column to discard larger 
molecules early in the assay is commonly used, but since HMGB1 usually is com-
plex bound in vivo, there may be a risk of miscalculation and false low readings. 
None of these assays distinguish between hyperacetylated HMGB1 or its redox 
forms. So far, only mass spectrometry allows such analysis. The mass spectrom-
etry technique has proven difficult, and in the last year suffered from scientific 
misconduct explicitly related to the measurements of HMGB1 reported from a 
British lab. The identification of different biologically active forms of HMGB1 
is, therefore, a challenge that lies ahead. 
The future clinical use of HMGB1 measurements would be greatly facilitated 
by the development of methods for bedside testing. The present ELISA is time-
consuming, however, at the 9th international DAMP and alarmin conference in 
Japan, which was held in November 2019, a new latex-immunoassay from Shino-
test Corporations was presented, and forecasted to soon be available for purchase. 
The latex-immunoassay, which performs HMGB1 concentration measurements 
in 10 minutes on regular hospital instruments, promises to reform the future of 
clinical HMGB1 testing. 
32
6.2 Interpretation of findings
Intensive care unit survivors are an increasing patient population that suffers from 
new onset of psychological, physical, and cognitive impairments. This purpose 
of this thesis was to identify possible new triggering factors in the development 
of PICS. 
In study I, we found no association between clinically diagnosed sepsis and 
delirium, and patients later self-rated cognitive function, and there may be several 
explanations to be found here. First, it is important to recognize that both sepsis 
and delirium are definitions that have evolved in order to understand and catego-
rize physiological conditions. Hence, one may acknowledge the complexity of 
different immune responses and that the clinical definitions may not be accurate 
enough considering the various conditions that occur during intensive care. One 
patient may have sepsis for two hours, whereas the neighbor has it for two weeks, 
and they both fall into the same category, and, therefore, there may be signifi-
cant differences in the immune response between such individuals. The same is 
true for delirium, which might be a reason why only the duration of delirium has 
proven to be associated with later cognitive impairment (7). Secondly, we used 
self-rated cognitive function in study I, and as we in study II found no correlation 
between patients’ subjective and objective cognitive function, there might still 
be an association between sepsis, delirium, and cognitive function, only that we 
did not capture it here in this setting. The strong correlation between subjective 
cognitive function and psychological distress was consistent in the two patient 
cohorts. What comes first is difficult to tell. Do patients get depressed because they 
are experiencing cognitive failures, or is depression affecting cognition? For the 
results from Study I and II, it also appears that psychological distress is only weakly 
correlated to worse objective cognitive function, but strongly correlated to worse 
subjective cognitive function. This implies that subjective cognitive performance 
also is a relevant patient outcome when it comes to rehabilitation and the ability 
to work, or, maybe, that it merely mirrors the psychological distress experienced.
As mentioned in the introduction, relevant measurements of cognitive function are 
a challenge for the ICU community. Neuropsychological test batteries are time-
consuming and require the presence of a test conductor. The CFQ has, therefore, 
gained interest as a simple tool for cognitive screening, as it can be filled in at 
home or easily at follow-up. Notably, although it has been used as a measure of 
cognitive function in ICU follow-ups (43, 145), we show in study II the lack of 
clinically relevant correlation between patients’ self-perceived cognitive failures 
and objective cognitive function assessed with neuropsychological tests. The 
difficulties with self-assessments have been discussed earlier in this section. 
Nevertheless, we cannot say that CFQ is a bad instrument for measuring patients’ 
cognitive failures in everyday-life, merely that it in ICU survivors do not reflect 
objectively measured cognitive impairments commonly found in this patient 
33
population. Both parts of cognition may be of relevance for the patient as they 
reflect different aspects of patients’ lives. The experience of cognitive failures in 
every-day life will most likely affect social life and the ability to perform at work. 
The same goes for cognitive impairment, and even though patients may not suffer 
from the cognitive impairment, family, and social network may. 
The potential link between inflammation and the development of PICS continues 
to intrigue us. The problem with inflammation is usually not why or how it starts, 
more how often it fails to resolve.  After the initial trigger of the immune response, 
affected tissues should restore to normal function, and the inflammation subside. 
When this fails, non-resolving inflammation appears (57).
In order to understand the causes of PICS, and especially cognitive impairment, 
several studies have investigated possible predictors, such as sepsis and delirium 
(7, 36). Results, however, have been contradictory (13). A possible mechanism in 
the development of cognitive impairment after intensive care shown in this thesis is 
the potential pro-inflammatory effect of HMGB1. We found that plasma HMGB1 
levels were elevated for up to six months after ICU discharge, a novel discovery. 
The kinetics observed here also support earlier studies of HMGB1 being a late 
mediator of inflammation (74, 122, 123). Many studies of HMGB1 in this context 
have been in sepsis patients or experimental sepsis models. We here, however, 
observed no difference in late plasma HMGB1 levels between patients diagnosed 
with sepsis or not at the ICU. This could be, as mentioned earlier, a result of the 
clinical definitions not being sufficiently precise, but most likely that both sterile 
and infectious stimuli triggers the same response regardless of the source. 
Measuring HMGB1 in the acute phase as a predictor of long-term outcome has 
proven difficult (146, 147). However, a recent paper by Ottestad et al. in trauma 
patients observed that not the initial plasma HMGB1 levels but a second wave of 
elevated plasma HMGB1 with onset a few hours after the trauma, was associated 
with worse outcomes (fewer ventilator-free days). As HMGB1 is released both 
passively (during necrosis and pyroptosis) and actively (from stressed and acti-
vated immune cells), one may guess this second wave may come from the latter.
The source of the exceptionally late, elevated levels of HMGB1 in ICU survi-
vors found here remains an enigma. It is tempting to speculate that it comes from 
actively released HMGB1, as other markers of cell destruction such as lactate 
dehydrogenase was low at follow-up (unpublished data). Additionally, consider-
ing the relatively short half-life of HMGB1, which varies between minutes and a 
few hours (148, 149), this also speaks for an ongoing, active release of HMGB1. 
Active release of HMGB1 is dependent on the translocation of HMGB1 from 
the nucleus to the cytosol. As mentioned earlier, the release is mediated through 
posttranslational modifications, with hyperacetylation of the two NLS sites (75), 
which translocate HMGB1 to the cytosol. Hyperacetylation of the NLS sites of 
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HMGB1 is in infection a result of activation of the JAK-STAT pathway (150). It 
would be intriguing to know if the JAK-STAT pathway is activated in this late 
mediated inflammation, but as we in study III and IV did not have the possibility 
to measures the degree of acetylation or redox form, one may only speculate in 
what form the plasma HMGB1 found here is. 
We found in study III that levels of HMGB1 were associated with sustained atten-
tion measured with RVP, one of the four cognitive tests chosen. Furthermore, we 
found that sustained attention was significantly impaired in our cohort compared 
to normative data, but not the other functions measured (i.e., executive function, 
visual memory, and working memory). This may indicate that sustained attention 
is the cognitive function most affected in ICU survivors tested here, or that the 
other three tests are limited in identifying cognitive impairment in this cohort. 
These findings might be an explanation of why we only observed an association 
between sustained attention and plasma levels of HMBG1, and not the other tests.
The lack of association between physical performance and plasma HMGB1 levels 
in study IV might have several explanations. The study design was predominantly 
constructed to identify new onset of cognitive impairment and not physical impair-
ment. We can, therefore, not with certainty, conclude that the physical impairments 
measured here are of recent onset, and possibly associated with effects related to 
elevated levels of HMGB1. Furthermore, earlier studies on HMGB1’s associa-
tion with muscle dysfunction have focused on local processes in muscle biopsies 
(129, 130), and it may be that plasma HMGB1 levels do not accurately reflect the 
intracellular milieu in muscle tissue.
6.3 Limitations
As ICU admissions predominantly are due to unexpected, acute illness, it pre-
cludes the assessment of baseline data. We, therefore, could not measure baseline 
cognitive function or baseline physical performance in the studies. In study II-III, 
however, we excluded patients with a history of cognitive impairment and screened 
patients with the IQCODE in which the patients’ next of kin score symptoms of 
cognitive decline, where patients with significant symptoms were excluded. We 
did this in order to be able to identify the new onset of cognitive impairments as 
a part of PICS, rather than to study preexisting cognitive impairment. As men-
tioned earlier are all four studies within this thesis follow-up studies, and the risk 
of selection bias in responders should, therefore, be considered. We also cannot 
rule out the fact that patients’ motivation to perform could have varied in between 
tests, due to fatigue or other emotional factors, considering that both the cognitive 
and physical tests demand some focus and willpower.
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7 FUTURE PERSPECTIVES
Many challenges lie ahead for the scientific ICU community for improving patients´ 
life after ICU. Structured, standardized test methods to identify ICU survivors at 
risk or in need of rehabilitation are needed. Possible future interventions to attenu-
ate the development of cognitive impairment in this growing patient population 
would be of great benefit. 
A clinically feasible way to measure HMGB1 with the promising new latex 
immune-assay would enable practical measurements that could help in our future 
understanding of HMGB1-biology in ICU patients. Another important step in 
order to understand the pathophysiology would be to identify the degree of acety-
lation and which redox forms that is released, a technique that regrettably is not 
easily available at the moment. It is tempting to speculate that further studies of 
lysophosphatidylcholine, the lipid that mediates the active exocytosis of HMGB1 
(76), could help us understand whether the HMGB1 released months after inten-
sive care is actively or passively released.
Four things have successfully targeted HMGB1 up to 24 h after onset of experimen-
tal sepsis and improved survival: anti-HMGB1 antibodies, vagal nerve stimulation 
RUĮQ$&K5DJRQLVWVDQGPRQRFORQDODQWLERGLHVDJDLQVW5$*(
Considering that these therapeutic approaches attenuate HMGB1, and based on 
the experimental results of alleviation of cognitive dysfunction (71), future pos-
sible anti-HMGB1 therapy might improve cognitive outcomes in ICU survivors. 
This, however, remains to be studied. 
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8 CONCLUSION
After critical illness, many patients suffer from debilitating long-term sequels that 
reduce quality of life and prevent the return to pre-morbid levels of function. Tools 
to easily predict, diagnose, and treat these important sequels after critical care are 
lacking. This thesis aims to identify clinical predictors of adverse cognitive out-
comes, map aspects of the underlying biology, and ideally suggest molecular targets 
amenable to therapeutic intervention. In conclusion, this effort aims to improve 
our understanding of cognitive impairment after critical illness and hopefully 
provide new knowledge that may contribute to improving patients´ life after ICU.
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9 POPULÄRVETENSKAPLIG 
SAMMANFATTNING
Allt fler överlever idag intensivvårdsbehandling. Frågan är - med vilken livskvalitet? 
Vid Karolinska Universitetssjukhuset i Solna studerar man följderna av intensiv-
vård, för att på så sätt underlätta rehabiliteringen efter livshotande sjukdom och 
intensivvård. Man har då funnit att en betydande del av patienterna uppger att de 
även månader efter intensivvård har påverkad kognitiv funktion, såsom problem 
med minne och uppmärksamhet. Förutom de kognitiva svårigheterna lider även 
upp till hälften av psykiska och fysiska problem. Dessa symtom kallas tillsammans 
för post-intensive care syndrome (PICS). Förutom att påverka patienterna i deras 
vardagsliv så försvåras även återgången till ett normalt liv och arbete. Orsakerna 
till denna ökade incidens av psykiska, fysiska och kognitiva problem är ännu inte 
kända. Blodförgiftning och akut förvirring (delirium) under intensivvård har i 
vissa studier visat på ett samband med senare kognitiva problem. I musmodeller 
av blodförgiftning har man hittat ett samband mellan ett pro-inflammatoriskt protein, 
High Mobility Group Box 1 (HMGB1), och kognitiv dysfunktion. Hur och om 
HMGB1 direkt eller indirekt påverkar kognitiv funktionsnedsättning är oklart, 
men det finns teorier att HMGB1 i kombination med andra pro-inflammatoriska 
proteiner aktiverar immunceller i hjärnan (mikroglia), vilket kan leda till neurotoxiska 
effekter. Intressant nog har det även visats sig att HMGB1 är förhöjt i blodet under 
en mycket längre tid än andra pro-inflammatoriska proteiner efter intensivvård. 
I musmodellen har man dessutom kunnat hämma HMGB1 flera dagar efter epi-
soden av blodförgiftning, med förbättrad kognitiv funktion som resultat. Det här 
är något som öppnar upp för möjliga, framtida terapier. 
Denna avhandlings inledande arbete undersökte sambandet mellan blodförgiftning 
och delirium under vårdtiden på intensiven och senare självskattad kognitiv funktion, 
samt sambandet mellan psykiska problem och självskattad kognitiv funktion. Vi 
fann där ett samband i det senare fallet men inget samband med blodförgiftning 
och delirium.  En orsak till detta skulle kunna vara att patienter har svårt att skatta 
den egna faktiska förmågan, framförallt den kognitiva. Den påföljande studien 
undersökte därför om patienters självskattade kognitiva funktion överensstämmer 
med objektiv kognitiv funktion testad genom formella neuropsykologiska tester. 
Vi kunde då visa att så inte var fallet, och man ska vara försiktig när man tolkar 
resultat från subjektivt skattade svarsformulär från intensivvårdspatienter. För att 
vidare kunna förstå orsaken till de svårigheter efter intensivvård som patienter lider 
av undersökte vi sambandet mellan den tidigare beskriva HMGB1 samt kognitiv 
funktion, tre och sex månader efter intensivvård. Vi fann då att nivåer av HMGB1 
i blodet var signifikant associerat med kognitiv funktionsnedsättning i form av 
patienters sänkta förmåga till uppmärksamhet. Detta är i linje med de resultat som 
kommit från experimentella musmodeller. 
Sammanfattningsvis syftar denna avhandling till att förbättra vår förståelse för 
kognitiv dysfunktion efter kritisk sjukdom och förhoppningsvis ge ny kunskap för 
att förbättra diagnos och behandling i denna stora patientpopulation.
38
10 ACKNOWLEDGEMENTS
I would like to express my sincerest appreciation to everyone who has supported 
me and contributed to this thesis. You are many, and I am so grateful for this!
Peder Olofsson, so brilliant, so supportive, so generous. I am profoundly grate-
ful for the opportunity you have given me, for the unlimited support, always with 
a happy smile even through intense arguments. For always challenging me to 
do my best, and patiently steering me in the right direction, even though I many 
times stubbornly wanted to do it my way. I am immensely impressed with how 
you supervised it all, it has been so much fun!
Peter Sackey, my first main supervisor. I am forever thankful for you believing 
in me as a medical student, and for later becoming your PhD student. For your 
unlimited energy, your expert clinical and scientific skills, your positive spirit 
and encouraging, caring support, especially when things were tough during those 
toddler years.
Sincere thanks to Anna Schandl, my co-supervisor, for always being there, and 
for your sensible and at all times bright inputs, science or not. For all the nice 
lunches, where conversation spanned from ICU follow-up to horses and dogs. I 
want to keep doing that!
Deep thanks to Michael Eberhardson, my co-supervisor, for often being the 
only sensible person in the room during intense arguments with the main supervi-
sor. I am sincerely grateful for all the clear and precise comments you made that 
improved my work during this PhD.
I am forever grateful to Ulf Andersson, the world-leading expert on HMGB1. 
For all the endless meetings where you patiently explained HMGB1-biology. For 
being such a genuinely nice person and always taking time to read manuscript or 
come for meetings. Your vast knowledge has had a great impact on the work done 
in this thesis, which I am sincerely thankful for!  
I want to express my sincerest gratitude to, Kristina Hambraeus-Jonzon, for 
hiring me, for always encouraging me, and for being a remarkable leader with 
both warmth and poise. We miss you!
Thank you, professor Lars I Eriksson, for always being positive and supportive, 
and for making an excellent research atmosphere at the clinic. 
Heartfelt thanks to Bijan Darvish, my boss, for always answering the phone, week-
end or weekday. For letting me have the time to do science, and for kindly accept-
ing my very long residency. So much looking forward to being back in the clinic!
39
Warm thanks to my mentor, Anders Sundqvist, for not only being a brilliant neu-
rologist, but also one of our family’s closest friends. Thanks for all the wisdom 
you have shared since I was a baby!
My sincerest thanks to Julie Lasselin, who have provided excellent and sharp 
comments. Without you we would have been lost in the field of psychoneuroim-
munology! Your skills and knowledge are impressive!
Heartfelt thanks to Eva Sundman, for your clever, precise, and at all times, sup-
portive comments!
Sincere thanks to Helena Sackey, for being a great tutor in med school and intro-
ducing me to your husband so this all could have a start!
I am grateful to Tatja Hirvikoski, whose advice has helped us.
I want to thank Kirsi Dolk, Petur Sigurjonsson, and Linda Rydén, for creating 
time for me to complete this thesis. Your patience with all of us is reverential!
Maggie Brohmée, the wiz of Heroma, I do not know how many times you saved 
me so I actually got a salary, how we miss you!
Eddie Weitzberg, thank you for always cheering me on, and for with great wit 
and skill creating such a warm and friendly research environment!
Thank you, Johan Nordström, my clinical supervisor, for all the encouraging 
words and expert clinical tips. You are an inspiration as a doctor and a fantastic 
tutor, and I am looking forward to come back to be part of it and to talk more 
about chickens!
I am grateful to Anders Oldner, my former co-supervisor, for always giving 
intelligent perspectives on things.
Many thanks to Helena Erlandsson-Harris, for letting me into your lab to do 
HMGB1 ELISA, and for great company at Icelandic conference!
I am grateful to Peter Lundbäck, for you assistance with HMGB1 and cytokine 
analysis.
None of this would have happened without the support from the fantastic research 
nurses, Caroline Keller, Elisabeth Hellgren, and Ola Friman. I will always be 
grateful for all your hard work in patient recruitment, collection of blood samples, 
and patient follow-up. You have my sincerest appreciation and admiration!
40
Matteo Bottai, a true grandmaster when it comes to statistics. I am so grateful to 
have had the privilege to work with you. You have shown me that statistics truly is 
an art form and that no violation of assumptions is a problem when you master it all. 
Thank you for sharing your expertise and benevolently having patience with me. 
Many thanks to Gabrielle Paulsson-Berne, for motivating me and giving me 
Beyoncé-power, and Stephen Malin for all your witty comments.
Sincere thanks to Beatriz and Angela Silveira, for assistance in data collection, 
for expert tips when it comes to laboratory technique and much more!  
To all my amazing colleagues at ANOPIVA/PMI. I have never seen so many 
talented persons in one place. I admire every one of you! I especially want to 
thank Maria Nilsson, without a doubt my strongest friend. For being by my side 
throughout this journey, from the time we did the introduction at ANOPIVA together 
and started our friendship sharing rooms in Ramis. For all the endless talks and 
debriefings after nightshifts, it has all been invaluable! Thank you, Julia Bell, 
for being my partner-in-crime when it comes to motherhood. For all the tips and 
support you have given during toddler years, and for always having such a wise 
perspective on things. Thank you, Anna Milton, co-PhD student, for all the nice 
chats during lunch or in the corridor, eager to read your thesis soon!
Heartfelt thanks to Jacob Larsson, for all the help and fun times during your 
research project! I really hope we get to spend more time doing science in the future!
Alessandro, April, Laura, Vladimir, Glykeria, Anton, Sanna, and all other 
members of the Olofsson lab! Thank you for with such warmth and hospitality 
letting me be a part of the group. For all the laughs and talks, that helps brighten 
the days during mellow autumn times. I am amazed by the scientific skills in the 
group, even though I never will be able to understand all the cool stuff you do! 
Sometimes science is so hard it just makes me sad ;-)
Sofia, Babs, and Annika, my med school friends, for all the fun in the past and 
in the present, our dinners and talks are so precious to me! 
Tina and Andreas, for being our extended Långgarn family, and for being our 
soul mates in everything – house, kids, horses, chickens, and now dogs!
Cilla, you are so much more than a best friend. Thanks for always being there. 
Much has happened since high school, but we stay the same. DG forever!
My cousins Maria, Amanda, and Monica for being the sisters I never had.
41
My mother- and father-in-law, Angela and Mats Lannerbro, always there, always 
helping. We would not have made it without you!
My brother Fille, always since childhood so sincerely kind to me, no conversation 
to deep, no question too complicated, I’m so blessed to have you close.
My parents, Ulla and Alf, you have laid the foundation that keeps me upright, I 
am so privileged, the love and support you have given me is endless. 
Edith and Clara, my lovely daughters, there is no love more deep and pure than 
the love I feel for you.
Jacob, my 100 % match, my yang, I love you, for everything! 
 
 
 
 
 
And finally, I would like to express my warmest gratitude to all patients 
included, for taking time to complete questionnaires and come to follow-up, 
and therefore making research possible.
This thesis was supported by grants from the Knut and Alice Wallenberg Foundation, 
the Swedish Medical Council (Vetenskapsrådet), Olle Engkvist Research Foundation, 
Torsten Söderberg Foundation, Svenska Läkaresällskapet and the Stockholm City 
Council (ALF)
42
11 REFERENCES
1. Lassen HC. A preliminary report on the 1952 epidemic of poliomyelitis in 
Copenhagen with special reference to the treatment of acute respiratory insuf-
ficiency. Lancet. 1953;1(6749):37-41.
2. Ibsen B. The anaesthetist’s viewpoint on the treatment of respiratory com-
plications in poliomyelitis during the epidemic in Copenhagen, 1952. Proc 
R Soc Med. 1954;47(1):72-4.
3. Reynolds LA, Tansey EM. History of British intensive care, c.1950–c.2000. . 
Wellcome Witnesses to Twentieth Century Medicine, vol 42 London: Queen 
Mary, University of London, 2011. 2011.
4. Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP. 
The variability of critical care bed numbers in Europe. Intensive Care Med. 
2012;38(10):1647-53.
5. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related 
to severe sepsis and septic shock among critically ill patients in Australia and 
New Zealand, 2000-2012. JAMA. 2014;311(13):1308-16.
6. van den Boogaard M, Schoonhoven L, Evers AW, van der Hoeven JG, van 
Achterberg T, Pickkers P. Delirium in critically ill patients: impact on long-
term health-related quality of life and cognitive functioning. Crit Care Med. 
2012;40(1):112-8.
7. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun 
BT, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 
2013;369(14):1306-16.
8. Jackson JC, Pandharipande PP, Girard TD, Brummel NE, Thompson JL, 
Hughes CG, et al. Depression, post-traumatic stress disorder, and functional 
disability in survivors of critical illness in the BRAIN-ICU study: a longitu-
dinal cohort study. Lancet Respir Med. 2014;2(5):369-79.
9. Davydow DS, Gifford JM, Desai SV, Needham DM, Bienvenu OJ. Posttraumatic 
stress disorder in general intensive care unit survivors: a systematic review. 
Gen Hosp Psychiatry. 2008;30(5):421-34.
10. Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression 
in general intensive care unit survivors: a systematic review. Intensive Care 
Med. 2009;35(5):796-809.
11. Cuthbertson BH, Scott J, Strachan M, Kilonzo M, Vale L. Quality of life 
before and after intensive care. Anaesthesia. 2005;60(4):332-9.
43
12. Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et 
al. Improving long-term outcomes after discharge from intensive care unit: 
report from a stakeholders’ conference. Crit Care Med. 2012;40(2):502-9.
13. Wolters AE, Slooter AJ, van der Kooi AW, van Dijk D. Cognitive impairment 
after intensive care unit admission: a systematic review. Intensive Care Med. 
2013;39(3):376-86.
14. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper 
A, et al. Functional disability 5 years after acute respiratory distress syndrome. 
N Engl J Med. 2011;364(14):1293-304.
15. Griffiths J, Fortune G, Barber V, Young JD. The prevalence of post traumatic 
stress disorder in survivors of ICU treatment: a systematic review. Intensive 
Care Med. 2007;33(9):1506-18.
16. Marra A, Pandharipande PP, Girard TD, Patel MB, Hughes CG, Jackson JC, 
et al. Co-Occurrence of Post-Intensive Care Syndrome Problems Among 406 
Survivors of Critical Illness. Crit Care Med. 2018;46(9):1393-401.
17. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the 
global burden of critical illness in adults. Lancet. 2010;376(9749):1339-46.
18. Norman BC, Jackson JC, Graves JA, Girard TD, Pandharipande PP, Brummel 
NE, et al. Employment Outcomes After Critical Illness: An Analysis of the 
Bringing to Light the Risk Factors and Incidence of Neuropsychological 
Dysfunction in ICU Survivors Cohort. Crit Care Med. 2016;44(11):2003-9.
19. Schandl A, Bottai M, Hellgren E, Sundin O, Sackey P. Gender differences in 
psychological morbidity and treatment in intensive care survivors - a cohort 
study. Crit Care. 2012;16(3):R80.
20. Crawford JR, Henry JD, Crombie C, Taylor EP. Normative data for the HADS 
from a large non-clinical sample. Br J Clin Psychol. 2001;40(4):429-34.
21. Cuthbertson BH, Rattray J, Campbell MK, Gager M, Roughton S, Smith 
A, et al. The PRaCTICaL study of nurse led, intensive care follow-up pro-
grammes for improving long term outcomes from critical illness: a pragmatic 
randomised controlled trial. Bmj-Brit Med J. 2009;339.
22. Brummel NE, Girard TD, Ely EW, Pandharipande PP, Morandi A, Hughes CG, 
et al. Feasibility and safety of early combined cognitive and physical therapy 
for critically ill medical and surgical patients: the Activity and Cognitive 
Therapy in ICU (ACT-ICU) trial. Intensive Care Med. 2014;40(3):370-9.
44
23. Jones C, Bäckman C, Capuzzo M, Egerod I, Flaatten H, Granja C, et al. 
Intensive care diaries reduce new onset post traumatic stress disorder following 
critical illness: a randomised, controlled trial. Crit Care. 2010;14(5):R168.
24. Mehlhorn J, Freytag A, Schmidt K, Brunkhorst FM, Graf J, Troitzsch U, et 
al. Rehabilitation interventions for postintensive care syndrome: a systematic 
review. Crit Care Med. 2014;42(5):1263-71.
25. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, 
Needham DM. Neuromuscular dysfunction acquired in critical illness: a sys-
tematic review. Intensive Care Med. 2007;33(11):1876-91.
26. Latronico N, Fenzi F, Recupero D, Guarneri B, Tomelleri G, Tonin P, et al. 
Critical illness myopathy and neuropathy. Lancet. 1996;347(9015):1579-82.
27. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major 
cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931-41.
28. Ali NA, O’Brien JM, Jr., Hoffmann SP, Phillips G, Garland A, Finley JC, et al. 
Acquired weakness, handgrip strength, and mortality in critically ill patients. 
Am J Respir Crit Care Med. 2008;178(3):261-8.
29. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados 
N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory 
distress syndrome. N Engl J Med. 2003;348(8):683-93.
30. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life 
in the five years after intensive care: a cohort study. Crit Care. 2010;14(1):R6.
31. Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. 
N Engl J Med. 2014;371(3):287-8.
32. Griffith DM, Vale ME, Campbell C, Lewis S, Walsh TS. Persistent inflam-
mation and recovery after intensive care: A systematic review. J Crit Care. 
2016;33:192-9.
33. Patel MB, Morandi A, Pandharipande PP. What’s new in post-ICU cognitive 
impairment? Intensive Care Med. 2015;41(4):708-11.
34. Jackson JC, Hart RP, Gordon SM, Shintani A, Truman B, May L, et al. Six-
month neuropsychological outcome of medical intensive care unit patients. 
Crit Care Med. 2003;31(4):1226-34.
35. Jackson JC, Gordon SM, Ely EW, Burger C, Hopkins RO. Research issues 
in the evaluation of cognitive impairment in intensive care unit survivors. 
Intensive Care Med. 2004;30(11):2009-16.
45
36. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impair-
ment and functional disability among survivors of severe sepsis. JAMA. 
2010;304(16):1787-94.
37. Guillamondegui OD, Richards JE, Ely EW, Jackson JC, Archer KR, Norris 
PR, et al. Does hypoxia affect intensive care unit delirium or long-term cog-
nitive impairment after multiple trauma without intracranial hemorrhage? J 
Trauma. 2011;70(4):910-5.
38. Sharifi F, Reisi P, Malek M. Angiotensin 1 receptor antagonist attenuates 
acute kidney injury-induced cognitive impairment and synaptic plasticity via 
modulating hippocampal oxidative stress. Life Sci. 2019;234:116775.
39. Hopkins RO, Wade D, Jackson JC. What’s new in cognitive function in ICU 
survivors. Intensive Care Med. 2017;43(2):223-5.
40. Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL, Shintani 
AK, et al. Delirium as a predictor of long-term cognitive impairment in sur-
vivors of critical illness. Crit Care Med. 2010;38(7):1513-20.
41. Sakusic A, O’Horo JC, Dziadzko M, Volha D, Ali R, Singh TD, et al. Potentially 
Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical 
Illness: A Systematic Review. Mayo Clin Proc. 2018;93(1):68-82.
42. Calsavara AJC, Nobre V, Barichello T, Teixeira AL. Post-sepsis cognitive 
impairment and associated risk factors: A systematic review. Aust Crit Care. 
2018;31(4):242-53.
43. Kerckhoffs MC, Kosasi FFL, Soliman IW, van Delden JJM, Cremer OL, de 
Lange DW, et al. Determinants of self-reported unacceptable outcome of 
intensive care treatment 1 year after discharge. Intensive Care Med. 2019.
44. Freund PA, Kasten N. How smart do you think you are? A meta-anal-
ysis on the validity of self-estimates of cognitive ability. Psychol Bull. 
2012;138(2):296-321.
45. Carrigan N, Barkus E. A systematic review of cognitive failures in daily life: 
Healthy populations. Neurosci Biobehav Rev. 2016;63:29-42.
46. Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive 
immune response. Curr Opin Immunol. 1997;9(1):4-9.
47. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 
2010;140(6):805-20.
48. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev 
Immunol. 2002;20:197-216.
46
49. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. 
Int Immunol. 2009;21(4):317-37.
50. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating 
mitochondrial DAMPs cause inflammatory responses to injury. Nature. 
2010;464(7285):104-7.
51. Forsberg A, Cervenka S, Jonsson Fagerlund M, Rasmussen LS, Zetterberg 
H, Erlandsson Harris H, et al. The immune response of the human brain to 
abdominal surgery. Ann Neurol. 2017;81(4):572-82.
52. Vincent JL, Taccone F, Schmit X. Classification, incidence, and outcomes of 
sepsis and multiple organ failure. Contrib Nephrol. 2007;156:64-74.
53. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer 
M, et al. The Third International Consensus Definitions for Sepsis and Septic 
Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
54. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. 
Crit Care Med. 1992;20(6):724-6.
55. Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of 
the effect of sepsis on survival. Department of Veterans Affairs Systemic 
Sepsis Cooperative Studies Group. JAMA. 1997;277(13):1058-63.
56. Yende S, Angus DC. Long-term outcomes from sepsis. Curr Infect Dis Rep. 
2007;9(5):382-6.
57. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-82.
58. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive 
Care Med. 2007;33(6):941-50.
59. Tsuruta R, Oda Y. A clinical perspective of sepsis-associated delirium. 
J Intensive Care. 2016;4:18.
60. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, et al. 
Delirium as a predictor of mortality in mechanically ventilated patients in 
the intensive care unit. JAMA. 2004;291(14):1753-62.
61. Thomason JW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive 
care unit delirium is an independent predictor of longer hospital stay: a pro-
spective analysis of 261 non-ventilated patients. Crit Care. 2005;9(4):R375-81.
62. Pandharipande P, Jackson J, Ely EW. Delirium: acute cognitive dysfunction 
in the critically ill. Curr Opin Crit Care. 2005;11(4):360-8.
47
63. Bruck E, Schandl A, Bottai M, Sackey P. The impact of sepsis, delirium, and 
psychological distress on self-rated cognitive function in ICU survivors-a 
prospective cohort study. J Intensive Care. 2018;6:2.
64. Lin SM, Liu CY, Wang CH, Lin HC, Huang CD, Huang PY, et al. The impact 
of delirium on the survival of mechanically ventilated patients. Crit Care Med. 
2004;32(11):2254-9.
65. Hughes CG, Patel MB, Pandharipande PP. Pathophysiology of acute brain 
dysfunction: what’s the cause of all this confusion? Curr Opin Crit Care. 
2012;18(5):518-26.
66. Zhang QH, Sheng ZY, Yao YM. Septic encephalopathy: when cytokines 
interact with acetylcholine in the brain. Mil Med Res. 2014;1:20.
67. Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T, 
et al. Long-term cognitive impairment, neuronal loss and reduced cortical 
cholinergic innervation after recovery from sepsis in a rodent model. Exp 
Neurol. 2007;204(2):733-40.
68. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflam-
mation to sickness and depression: when the immune system subjugates the 
brain. Nat Rev Neurosci. 2008;9(1):46-56.
69. Shattuck EC, Muehlenbein MP. Human sickness behavior: Ultimate and 
proximate explanations. Am J Phys Anthropol. 2015;157(1):1-18.
70. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural 
Transm (Vienna). 2012;119(2):197-209.
71. Chavan SS, Huerta PT, Robbiati S, Valdes-Ferrer SI, Ochani M, Dancho M, 
et al. HMGB1 Mediates Cognitive Impairment in Sepsis Survivors. Mol Med. 
2012.
72. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated 
proteins with a high content of acidic and basic amino acids. Eur J Biochem. 
1973;38(1):14-9.
73. Weir HM, Kraulis PJ, Hill CS, Raine AR, Laue ED, Thomas JO. Structure of 
the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12(4):1311-9.
74. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, 
et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 
1999;285(5425):248-51.
75. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic 
cells hyperacetylate chromatin protein HMGB1 to redirect it towards secre-
tion. EMBO J. 2003;22(20):5551-60.
48
76. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, et al. 
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, 
vesicle-mediated secretory pathway. EMBO Rep. 2002;3(10):995-1001.
77. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear 
weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-42.
78. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secre-
tory route of the leaderless protein interleukin 1beta involves exocytosis of 
endolysosome-related vesicles. Mol Biol Cell. 1999;10(5):1463-75.
79. Antoine DJ, Harris HE, Andersson U, Tracey KJ, Bianchi ME. A systematic 
nomenclature for the redox states of high mobility group box (HMGB) pro-
teins. Mol Med. 2014;20:135-7.
80. Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target 
in inflammatory diseases. Expert Opin Ther Targets. 2018;22(3):263-77.
81. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals 
through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174-9.
82. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold 
Spring Harb Perspect Biol. 2009;1(6):a001651.
83. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: 
IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990;4(11):2860-7.
84. Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) 
operates as an alarmin outside as well as inside cells. Semin Immunol. 2018.
85. Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The Endotoxin 
Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. 
Immunity. 2018;49(4):740-53 e7.
86. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. 
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by 
forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 
2012;209(3):551-63.
87. Wahamaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger 
AC, Andersson U, et al. High mobility group box protein 1 in complex with 
lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype 
in synovial fibroblasts. Arthritis Res Ther. 2011;13(4):R136.
88. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, 
et al. Non-canonical inflammasome activation targets caspase-11. Nature. 
2011;479(7371):117-21.
49
89. Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, et al. 
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. 
Nature. 2015;526(7575):666-71.
90. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflam-
mation. Nat Rev Microbiol. 2009;7(2):99-109.
91. Cheng KT, Xiong S, Ye Z, Hong Z, Di A, Tsang KM, et al. Caspase-11-
mediated endothelial pyroptosis underlies endotoxemia-induced lung injury. 
J Clin Invest. 2017;127(11):4124-35.
92. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health 
and disease. Mol Aspects Med. 2014;40:1-116.
93. Sundman E, Olofsson PS. Neural control of the immune system. Adv Physiol 
Educ. 2014;38(2):135-9.
94. Cox MA, Duncan GS, Lin GHY, Steinberg BE, Yu LX, Brenner D, et al. 
Choline acetyltransferase-expressing T cells are required to control chronic 
viral infection. Science. 2019;363(6427):639-44.
95. Olofsson PS, Steinberg BE, Sobbi R, Cox MA, Ahmed MN, Oswald M, et 
al. Blood pressure regulation by CD4(+) lymphocytes expressing choline 
acetyltransferase. Nat Biotechnol. 2016;34(10):1066-71.
96. Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. 
J Exp Med. 2012;209(6):1057-68.
97. Olofsson PS, Katz DA, Rosas-Ballina M, Levine YA, Ochani M, Valdes-Ferrer 
SI, et al. alpha7 nicotinic acetylcholine receptor (alpha7nAChR) expression 
in bone marrow-derived non-T cells is required for the inflammatory reflex. 
Mol Med. 2012;18:539-43.
98. Lu B, Kwan K, Levine YA, Olofsson PS, Yang H, Li J, et al. alpha7 nicotinic 
acetylcholine receptor signaling inhibits inflammasome activation by prevent-
ing mitochondrial DNA release. Mol Med. 2014;20:350-8.
99. Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-
Ballina M, et al. Transcutaneous vagus nerve stimulation reduces serum high 
mobility group box 1 levels and improves survival in murine sepsis. Crit Care 
Med. 2007;35(12):2762-8.
100. Olofsson PS, Tracey KJ. Bioelectronic medicine: technology targeting molecular 
mechanisms for therapy. J Intern Med. 2017;282(1):3-4.
101. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat 
Rev Neurol. 2010;6(4):193-201.
50
102. Fonken LK, Frank MG, Kitt MM, D’Angelo HM, Norden DM, Weber MD, 
et al. The Alarmin HMGB1 Mediates Age-Induced Neuroinflammatory 
Priming. J Neurosci. 2016;36(30):7946-56.
103. Agalave NM, Larsson M, Abdelmoaty S, Su J, Baharpoor A, Lundback P, 
et al. Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity 
and glial activation and regulates pain-like behavior in experimental arthritis. 
Pain. 2014;155(9):1802-13.
104. Terrando N, Rei Fidalgo A, Vizcaychipi M, Cibelli M, Ma D, Monaco C, et 
al. The impact of IL-1 modulation on the development of lipopolysaccharide-
induced cognitive dysfunction. Crit Care. 2010;14(3):R88.
105. Festoff BW, Sajja RK, van Dreden P, Cucullo L. HMGB1 and thrombin 
mediate the blood-brain barrier dysfunction acting as biomarkers of neuro-
inflammation and progression to neurodegeneration in Alzheimer’s disease. 
J Neuroinflamm. 2016;13.
106. Xu B, Lang LM, Li SZ, Guo JR, Wang JF, Yang HM, et al. Microglia Activated 
by Excess Cortisol Induce HMGB1 Acetylation and Neuroinflammation in the 
Hippocampal DG Region of Mice Following Cold Exposure. Biomolecules. 
2019;9(9).
107. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: 
excitatory times ahead. Lancet Neurol. 2008;7(8):742-55.
108. Pedrazzi M, Averna M, Sparatore B, Patrone M, Salamino F, Marcoli M, et al. 
Potentiation of NMDA receptor-dependent cell responses by extracellular 
high mobility group box 1 protein. PLoS One. 2012;7(8):e44518.
109. Webster KM, Sun M, Crack PJ, O’Brien TJ, Shultz SR, Semple BD. 
Age-dependent release of high-mobility group box protein-1 and cellular 
neuroinflammation after traumatic brain injury in mice. J Comp Neurol. 
2019;527(6):1102-17.
110. Singh V, Roth S, Veltkamp R, Liesz A. HMGB1 as a Key Mediator of Immune 
Mechanisms in Ischemic Stroke. Antioxid Redox Signal. 2016;24(12):635-51.
111. Ravizza T, Terrone G, Salamone A, Frigerio F, Balosso S, Antoine DJ, et al. 
High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic 
biomarker for epilepsy. Brain Behav Immun. 2018;72:14-21.
112. Meneghini V, Bortolotto V, Francese MT, Dellarole A, Carraro L, Terzieva S, 
et al. High-mobility group box-1 protein and beta-amyloid oligomers promote 
neuronal differentiation of adult hippocampal neural progenitors via receptor 
for advanced glycation end products/nuclear factor-kappaB axis: relevance 
for Alzheimer’s disease. J Neurosci. 2013;33(14):6047-59.
51
113. Wang B, Lian YJ, Su WJ, Peng W, Dong X, Liu LL, et al. HMGB1 mediates 
depressive behavior induced by chronic stress through activating the kynure-
nine pathway. Brain Behav Immun. 2018;72:51-60.
114. Terrando N, Yang T, Wang X, Fang J, Cao M, Andersson U, et al. Systemic 
HMGB1 Neutralization Prevents Postoperative Neurocognitive Dysfunction 
in Aged Rats. Front Immunol. 2016;7:441.
115. He HJ, Wang Y, Le Y, Duan KM, Yan XB, Liao Q, et al. Surgery upregulates 
high mobility group box-1 and disrupts the blood-brain barrier causing cog-
nitive dysfunction in aged rats. CNS Neurosci Ther. 2012;18(12):994-1002.
116. Zaghloul N, Addorisio ME, Silverman HA, Patel HL, Valdes-Ferrer SI, 
Ayasolla KR, et al. Forebrain Cholinergic Dysfunction and Systemic and Brain 
Inflammation in Murine Sepsis Survivors. Front Immunol. 2017;8:1673.
117. Terrando N, Eriksson LI, Ryu JK, Yang T, Monaco C, Feldmann M, et al. 
Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol. 
2011;70(6):986-95.
118. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. 
Recombinant human interleukin 1 receptor antagonist in the treatment of 
patients with sepsis syndrome. Results from a randomized, double-blind, 
placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. 
JAMA. 1994;271(23):1836-43.
119. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. 
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion 
protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 
1996;334(26):1697-702.
120. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. 
Efficacy and safety of monoclonal antibody to human tumor necrosis factor 
alpha in patients with sepsis syndrome. A randomized, controlled, double-
blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 
1995;273(12):934-41.
121. Waage A, Halstensen A, Espevik T. Association between tumour necrosis 
factor in serum and fatal outcome in patients with meningococcal disease. 
Lancet. 1987;1(8529):355-7.
122. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, et al. 
Circulating high-mobility group box 1 (HMGB1) concentrations are elevated 
in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit 
Care Med. 2007;35(4):1061-7.
52
123. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman 
G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein 
(HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 
2005;33(3):564-73.
124. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, et al. High-
mobility group box 1 protein plasma concentrations during septic shock. 
Intensive Care Med. 2007;33(8):1347-53.
125. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflam-
mation and infection. Annu Rev Immunol. 2011;29:139-62.
126. Bloch S, Polkey MI, Griffiths M, Kemp P. Molecular mechanisms of intensive 
care unit-acquired weakness. Eur Respir J. 2012;39(4):1000-11.
127. Ochala J, Gustafson AM, Diez ML, Renaud G, Li M, Aare S, et al. Preferential 
skeletal muscle myosin loss in response to mechanical silencing in a novel 
rat intensive care unit model: underlying mechanisms. J Physiol. 2011;589(Pt 
8):2007-26.
128. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, et al. 
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 
2004;119(2):285-98.
129. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, et al. 
TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann 
Rheum Dis. 2013;72(8):1390-9.
130. Riuzzi F, Sorci G, Sagheddu R, Chiappalupi S, Salvadori L, Donato R. RAGE 
in the pathophysiology of skeletal muscle. J Cachexia Sarcopenia Muscle. 
2018;9(7):1213-34.
131. World Medical A. World Medical Association Declaration of Helsinki: 
ethical principles for medical research involving human subjects. JAMA. 
2013;310(20):2191-4.
132. van den Boogaard M, Pickkers P, Slooter AJ, Kuiper MA, Spronk PE, van der 
Voort PH, et al. Development and validation of PRE-DELIRIC (PREdiction 
of DELIRium in ICu patients) delirium prediction model for intensive care 
patients: observational multicentre study. BMJ. 2012;344:e420.
133. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium 
in mechanically ventilated patients: validity and reliability of the confu-
sion assessment method for the intensive care unit (CAM-ICU). JAMA. 
2001;286(21):2703-10.
53
134. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures 
Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21 (Pt 1):1-16.
135. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta 
Psychiatr Scand. 1983;67(6):361-70.
136. Stoll C, Kapfhammer HP, Rothenhäusler HB, Haller M, Briegel J, Schmidt 
M, et al. Sensitivity and specificity of a screening test to document traumatic 
experiences and to diagnose post-traumatic stress disorder in ARDS patients 
after intensive care treatment. Intensive Care Med. 1999;25(7):697-704.
137. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly 
(IQCODE): a review. Int Psychogeriatr. 2004;16(3):275-93.
138. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman 
CS, et al. Developing a New Definition and Assessing New Clinical Criteria 
for Septic Shock: For the Third International Consensus Definitions for Sepsis 
and Septic Shock (Sepsis-3). JAMA. 2016;315(8):775-87.
139. Lasselin J, Treadway MT, Lacourt TE, Soop A, Olsson MJ, Karshikoff B, 
et al. Lipopolysaccharide Alters Motivated Behavior in a Monetary Reward 
Task: a Randomized Trial. Neuropsychopharmacology. 2017;42(4):801-10.
140. Guenther CL, Alicke MD. Deconstructing the better-than-average effect. 
J Pers Soc Psychol. 2010;99(5):755-70.
141. Kruger J, Dunning D. Unskilled and unaware of it: how difficulties in recog-
nizing one’s own incompetence lead to inflated self-assessments. J Pers Soc 
Psychol. 1999;77(6):1121-34.
142. de Winter JC, Dodou D, Hancock PA. On the paradoxical decrease of self-
reported cognitive failures with age. Ergonomics. 2015;58(9):1471-86.
143. Wilhelm O, Witthoft M, Schipolowski S. Self-Reported Cognitive Failures 
Competing Measurement Models and Self-Report Correlates. J Individ Dif. 
2010;31(1):1-14.
144. Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I. New high mobility 
group box 1 assay system. Clin Chim Acta. 2006;372(1-2):173-8.
145. Wassenaar A, de Reus J, Donders ART, Schoonhoven L, Cremer OL, de Lange 
DW, et al. Development and Validation of an Abbreviated Questionnaire to 
Easily Measure Cognitive Failure in ICU Survivors: A Multicenter Study. 
Crit Care Med. 2018;46(1):79-84.
146. Yagmur E, Buendgens L, Herbers U, Beeretz A, Weiskirchen R, Koek GH, et 
al. High mobility group box 1 as a biomarker in critically ill patients. J Clin 
Lab Anal. 2018;32(8):e22584.
54
147. Giannoudis PV, Mallina R, Harwood P, Perry S, Sante ED, Pape HC. Pattern 
of release and relationship between HMGB-1 and IL-6 following blunt trauma. 
Injury. 2010;41(12):1323-7.
148. Ottestad W, Rognes IN, Pischke SE, Mollnes TE, Andersson U, Eken T. 
Biphasic Release of the Alarmin High Mobility Group Box 1 Protein Early After 
Trauma Predicts Poor Clinical Outcome. Crit Care Med. 2019;47(8):e614-e22.
149. Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, et al. 
Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extra-
cellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem. 
2013;288(17):11621-7.
150. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, et al. 
JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear trans-
location. Proc Natl Acad Sci U S A. 2014;111(8):3068-73.
151. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing 
established sepsis with antagonists of endogenous high-mobility group box 
1. Proc Natl Acad Sci U S A. 2004;101(1):296-301.
152. Lutterloh EC, Opal SM, Pittman DD, Keith JC, Jr., Tan XY, Clancy BM, et al. 
Inhibition of the RAGE products increases survival in experimental models 
of severe sepsis and systemic infection. Crit Care. 2007;11(6):R122.
153. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin 
X, et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 
improves survival in murine endotoxemia and severe sepsis. Crit Care Med. 
2007;35(4):1139-44.
 LO

